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 Amyotrophic lateral sclerosis (ALS) is an aggressive neurodegenerative disease 
in which motor neurons selectively degenerate, leading to paralysis and death. Rare 
causal mutations in FUS and TARDBP implicated RNA binding proteins and RNA 
metabolism in ALS disease mechanisms. The absence of faithful animal models has 
impeded precise understanding of the impact of ALS mutations on all functions of ALS-
associated proteins. In my graduate studies, I used a novel, animal model of FUS-ALS 
to explore gain of function disease mechanisms and observed specific, aberrant 
interactions between mutant FUS and other RNA binding proteins including hnRNP U. 
Genetic experiments indicate loss of hnRNP U is toxic to motor neurons, suggesting 
mutant FUS toxicity may result from hnRNP U sequestration and loss of function. In a 
parallel series of experiments, I also generated novel knock-in mouse models of ALS 
expressing pathogenic TARDBP mutations to address the flaws of existing model 
systems and to study the functional consequences of disease-related mutations. We 
demonstrate that the ALS mutant alleles TDP-43M337V and TDP-43G298S are fully 
functional and are insufficient to cause age-dependent motor neuron pathology, 
indicating that physiological levels of mutant TDP-43 are alone insufficient to initiate 
disease. This model enables future exploration of the interaction between genetic and 
environmental factors that lead to TDP-43 toxicity in ALS and related disorders. 
Collectively, our findings suggest a gain of function mechanism of toxicity in which 
 
 
mutations and aging, with other factors, alter the local concentration of RNA binding 
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Chapter 1: Introduction 
 
 Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease in 
the United States is a progressive, mostly adult onset, motor neuron disease leading to 
paralysis and death. In 90% of ALS patients, there is no known family history, and in 
these sporadic cases, the cause of disease is mostly unknown. The 10% that are 
familial has led to the identification of a growing number of genes in which mutations 
have been found to cause the disease, and spontaneous mutations in these same 
genes account for a small percentage of sporadic ALS cases. Clinical and pathological 
similarities between sporadic and familial ALS suggest that mutations in a variety of 
genes in addition to unidentified environmental causes converge in common 
mechanisms of neurodegeneration, however the nature of these mechanisms is still 
unknown. Riluzole is the only approved therapeutic for the disease and its benefit is 
modest, extending the lifespan of patients by only 3-6 months (Rowland & Shneider 
2001). The absence of effective therapeutics almost 150 years after the description of 
the disease necessitates further research into mechanisms of disease. 
 
1.1 Early ALS research 
 Jean-Martin Charcot first described ALS in 1874, and his description of the 
disease remains largely unchanged from how we know ALS today. He described 
progressive paralysis accompanied by muscle rigidity and atrophy in the absence of 
sensory loss, resulting in death in 2 or 3 years. He also noted that onset was associated 
with a focality, with symptoms starting in the limb or bulbar regions and in some cases 
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on just one side of the body, and certain muscles such as the rectum were spared. 
Perhaps most impressive was his ability to correlate clinical observations with 
pathological observations upon autopsy. In this way he named the disease Amyotrophic 
lateral sclerosis, after the observed muscle atrophy (amyotrophy) and weakness 
associated with the hardening of the lateral columns of the spinal cord (lateral sclerosis) 
(Rowland & Shneider 2001; Rowland 2001).  
Ensuing research described many pathological features of the disease, which 
include motor neuron loss, gliosis, aberrant inclusions, and neurofilament accumulation 
(Hirano et al. 1967; Schiffer et al. 1996; Earle et al. 1969; Leigh et al. 1988). These and 
other observations led to many early theories on the mechanisms of neurodegeneration 
including toxic environmental factors, metabolic defects, immunologic abnormality, viral 
infection, heavy metal toxicity, axonal transport defects, DNA damage, and aging 
(Mitsumoto et al. 1988). Through the course of ALS research, excitement for some of 
these mechanisms has waned, while others remain active areas of study.  
ALS is diagnosed clinically by signs of upper and lower motor neuron 
degeneration accompanied by a progressive spread of symptoms and the absence of 
evidence suggesting other diseases (Brooks et al. 2000). On a pathological level, ALS 
is diagnosed by loss of upper and lower motor neurons and the degeneration of the 
corticospinal tract, and in addition presence of ubiquitinated, cytoplasmic inclusions 
(Geser et al. 2010). 
Clinical observations suggest a multifactorial etiology of ALS with family history, 
sex, and age as strong risk factors (Oskarsson et al. 2015). Family history led to the 
identification of causal mutations in familial ALS, which are now known to occur de novo 
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in sporadic cases. ALS is also ~1.6 times more common in men than women, indicating 
sex as a risk factor (Mitsumoto et al. 1988). With few exceptions, ALS is an adult onset 
disorder, with onset typically above the age of 40 (Rowland & Shneider 2001). This is 
true in both familial and sporadic ALS, suggesting age as a precipitating factor even in 
the presence of a genetic mutation. Environmental factors are also implicated from high 
ALS prevalence in Guam that cannot be explained by founder effects (McGeer et al. 
1997) and additional epidemiological studies (Oskarsson et al. 2015). Lastly, focal onset 
of muscle weakness that progresses contiguously in the brain and spinal cord suggests 
that certain factors selectively induce neurodegeneration locally, even in the presence 
of ubiquitous causal mutations (Ravits et al. 2007). Together, these data paint a 
complex picture of ALS as a disease with multiple underlying causes. 
 
1.2 SOD1 in ALS 
A major breakthrough in ALS research came in 1993 with the identification of 
causal mutations in 20% of familial ALS cases in Superoxide Dismutase 1 (SOD1) 
(Rosen et al. 1993), which encodes a ubiquitously expressed enzyme that breaks down 
reactive oxygen species. This changed the landscape of ALS research as it allowed 
scientists to create animal models of the disease and therefore move from clinical and 
post mortem descriptive analyses to mechanistic experimentation. The clinical and 
pathological similarities between familial and sporadic ALS suggested that modeling the 





SOD1 animal models 
 SOD1 animal models were generated immediately after the discovery of causal 
mutations. In general, overexpression of mutant, but not wild type, SOD1 leads to a 
progressive motor phenotype that recapitulates key features of ALS in humans, 
including motor neuron loss, premature death, and SOD1 aggregation, with varying 
ages of disease onset and death (Turner & Talbot 2008). Further experiments 
determined the motor neuron degeneration was associated with a toxic gain of function 
and not an SOD1 loss of function, as expression of mutant protein led to a motor 
phenotype independent of enzyme activity (Gurney et al. 1994). 
 SOD1 models permitted the identification of molecular and anatomical changes 
that were early, presymptomatic events in the disease course. Defects in the 
neuromuscular junction (NMJ) were identified as precursors to motor neuron loss, 
providing evidence in support of a “dying-back” hypothesis in which the axon retracts 
from the NMJ until ultimately its cell body degenerates in the spinal cord (Fischer et al. 
2004). Endoplasmic reticulum (ER) stress was identified as an early marker of disease, 
and fast-fatigable motor neurons were revealed to be preferentially vulnerable, dying 
before those innervating slow-twitch muscles (Frey et al. 2000; Pun et al. 2006; Saxena 
et al. 2009). 
Additionally, SOD1 genetic studies implicated both cell autonomous and non-cell 
autonomous mechanisms of neurodegeneration. Expression of mutant SOD1 in motor 
neurons seems to govern disease onset, and expression in microglia, astrocytes, 
oligodendrocytes, Schwann cells, and potentially other cell types also affects the course 
of motor neuron disease (Yamanaka, Chun, et al. 2008; Boillée et al. 2006; Clement et 
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al. 2003; Lee et al. 2012; Ferraiuolo et al. 2016; Lobsiger et al. 2009; Yamanaka, 
Boillee, et al. 2008). In addition, specific mechanisms have been proposed in which 
astrocytes and microglia release factors that are toxic to motor neurons and induce their 
degeneration (Nagai et al. 2007; Frakes et al. 2014). 
SOD1 models in vitro and in vivo have implicated a number of mechanisms in 
ALS pathogenesis including excitotoxicity, oxidative stress, ER stress, mitochondrial 
dysfunction, axon transport defects, prion-like propagation of aggregates, and glial 
toxicity (Fig. 1.1) (Hayashi et al. 2016). The most aggressive SOD1 mouse model 
reaches end stages of disease by 4 months (Gurney et al. 1994) and is thus an 
experimentally tractable system in which to explore genetic modifiers and ALS 
treatments targeting each of these mechanisms. 
 
Shortcomings of the SOD1 model 
Many genetic experiments and therapeutic trials in SOD1 mice revealed 
modifiers of the disease phenotype, however thus far none have translated into clinical 
success in patients (Mitsumoto et al. 2014; Turner & Talbot 2008). Many factors may 
explain the lack of translation from SOD1 mouse models to clinical benefit. There is 
evidence that confounding variables such as gender, transgene copy number, and other 
factors impacted the results and when controlled for, erase the phenotypic benefit of 
many compounds (Scott et al. 2008). Additionally, there is a need for improved 
preclinical testing, clinical trial design, and ALS biomarkers to overcome the challenges 




Close inspection of SOD1 animal models suggests their design may also 
introduce experimental artifacts that underlie the absence of translatable therapeutics. 
First, SOD1 transgenic mice that display a motor neuron phenotype rely on dramatic 
protein overexpression, which in some cases is 20-fold higher than endogenous protein 
levels (Julien & Kriz 2006). Many models have described a dose dependence of the 
phenotype, whereby levels of overexpression correlate with phenotypic severity (Gurney 
et al. 1994; Bruijn et al. 1997). In animals overexpressing wild type SOD1, an overt 
motor neuron phenotype is absent, however in old mice there is indication of pathology 
(Dal Canto & Gurney 1994). An SOD1 knock-in mouse, in which mutations were 
inserted directly into the SOD1 genetic locus to avoid overexpression artifacts, did not 
show any heterozygous phenotype, and the homozygous phenotype was shown to 
arise from loss of SOD1 function (Joyce et al. 2014). Taken together, these data 
indicate that overexpression is itself toxic, and while it conveniently accelerates the 
phenotype, it may also lead to molecular changes that are unrelated to ALS, thereby 
confounding ALS studies. 
In addition to suboptimal model design, the discovery of TDP-43 pathology in 
2006 dissociated SOD1-ALS from the rest of ALS cases. We now know that TDP-43 
inclusions are present in almost all cases of ALS, suggesting that it is a common 
downstream mediator of neurodegeneration. However TDP-43 pathology is notably 
absent in patients with SOD1 mutations (Mackenzie et al. 2007). While ALS patients 
with SOD1 mutations are similar to other sporadic and familial patients clinically, the 
absence of TDP-43 pathology in these patients suggests that SOD1 causes 
neurodegeneration by a distinct disease mechanism. Therefore, mechanistic insights 
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gained from SOD1 animal models may not be broadly relevant in ALS. Subsequent 
genetic advances identified ALS-causing mutations in many other genes, implicating 
new mechanisms and pathways in the degenerative cascade and enabling the 
development of novel genetic systems to compare to SOD1 models and to test potential 
therapeutics. 
 
1.3 Genetics in ALS 
That mutations in SOD1 cause only 20% of familial ALS cases suggested 
mutations in additional genes also cause the disease. The development of high-
throughput DNA sequencing technology led to the rapid identification of mutations in 
more than 20 new ALS-related genes (Table 1.1), including TARDBP (encoding TDP-
43) and Fused in Sarcoma (FUS), and a significant advance in 2011 identified a repeat 
expansion in C9orf72, the gene most commonly associated with familial and sporadic 
ALS and frontotemporal dementia (FTD) (Al-Chalabi et al. 2012; Robberecht & Philips 
2013; Guerreiro et al. 2015). These genes span broad functional categories including 
enzymes, and other proteins involved in RNA metabolism, proteostasis, neuronal 
excitation, and cellular transport. Genetic advances have also emphasized the 
multifactorial nature of ALS as not all ALS mutations are fully penetrant, suggesting 
additional factors are required to lead to disease onset (Borghero et al. 2014). 
Additionally, genetics advances have strengthened the connection between ALS and 
other neurodegenerative diseases. 
 
ALS as a spectrum disorder 
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 ALS is clinically and pathologically related to FTD, and the discovery of new 
genes associated with both disorders supported the idea of ALS as a spectrum disorder 
whose mechanisms overlap with those of other neurodegenerative diseases. Mutations 
in TARDBP, ubiquilin-2, and valosin-containing protein (VCP) cause both ALS and FTD, 
and the most common genetic cause of both diseases is a hexanucleotide repeat 
expansion in C9orf72 (Morris et al. 2012). TDP-43 and FUS aggregates are also found 
in both diseases (Morris et al. 2012), demonstrating that ALS and FTD can both 
manifest from the same underlying causes and disease processes. 
 Additionally, other ALS-related genes have been implicated in other diseases. 
For example, angiogenin is related to Parkinson’s disease, senataxin to ataxia 
oculomotor apraxia type 2, and VCP to Paget’s disease of bone and inclusion body 
myopathy; repeats in ataxin-2 cause spinocerebellar ataxia type 2, and optineurin 
mutations cause glaucoma and ataxia (Al-Chalabi et al. 2012). Together these 
observations suggest that ALS may be part of a larger disease spectrum, and therefore 
understanding mechanisms of neurodegeneration in ALS may be broadly applicable to 
a host of other diseases. 
 
RNA metabolism as a common theme 
While genetic developments have been useful in implicating new mechanisms in 
ALS, they also raise questions as to how seemingly different underlying causes can 
lead to the same presentation of motor neuron disease. One theme that arose from the 
genetic discoveries is that of RNA metabolism. Many newly identified causal genes 
including TARDBP and FUS encode RNA binding proteins, suggesting that 
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dysregulated RNA metabolism may be a common disease mechanism. The discovery 
of C9orf72 repeat expansions as the most common genetic cause further implicated 
RNA toxicity as a mechanism, as repeat expansions in other diseases are pathogenic 
through RNA toxicity mechanisms (Kanadia et al. 2003; Sellier et al. 2010). Additionally, 
the near-ubiquitous presence of aggregates composed of RNA-binding-protein TDP-43 
in ALS cases suggested RNA metabolism plays a central role in the disease. 
 
As this thesis will focus on the role of TDP-43 and FUS, it is important to first 
consider the known roles of these two RNA binding proteins in the cell and in disease. 
 
1.4 TDP-43 in ALS 
 As described below, TDP-43 aggregates are found in almost all ALS cases and 
mutations in TARDBP also cause disease, suggesting TDP-43 plays a central role in 
ALS. Here I will survey TDP-43 literature including pathology in ALS, protein structure 
and function, animal models, and disease mechanisms in order to provide rationale for 
the generation of the TDP-43 knock-in model. 
 
TDP-43 mutations and pathology 
 TDP-43 was identified as the major protein component of insoluble, ubiquitinated 
inclusions in both ALS and frontotemporal lobar degeneration (FTLD) in 2006, changing 
the focus of ALS research. One report identified TDP-43 inclusions in the spinal cord of 
ALS cases and the brain of FTD and Alzheimer’s disease cases, and indicated that 
TDP-43 was abnormally phosphorylated (Arai et al. 2006). A second report identified 
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TDP-43 ubiquitinated inclusions in the brain and spinal cord of FTD and ALS cases with 
C-terminal TDP-43 fragments (CTFs), phosphorylated TDP-43, and nuclear exclusion of 
affected neurons (Neumann et al. 2006). Further characterization of TDP-43 pathology 
revealed widespread distribution of hyperphosphorylated TDP-43 and 25 KDa and 35 
KDa CTFs in brain and spinal cord neurons and glia of both ALS and FTD cases, and 
there was a greater degree of pathology in the more clinically affected regions (Geser et 
al. 2009; Neumann et al. 2007; Schiffer et al. 1996). TDP-43 inclusions also contain 
other proteins such as the stress granule marker TIA-1 (Liu-Yesucevitz et al. 2010). 
TDP-43 pathology is found in almost all sporadic and familial cases of ALS, with the 
exception of those with SOD1 or FUS mutations. 
This discovery also supported the idea of ALS and FTD as a mechanistically 
related spectrum of disorders, referred to as multisystem TDP-43 proteinopathies 
(Geser et al. 2009). TDP-43 pathology was also observed in many other diseases 
including Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, myopathies, 
Pick’s disease, and others, suggesting broad relevance of TDP-43 to disease 
(Nakashima-Yasuda et al. 2007; Schwab et al. 2008; Arai et al. 2009; Küsters et al. 
2009; Lin & Dickson 2008).  
Not only does TDP-43 aggregate in ALS but TARDBP is also mutated in ~4% of 
familial and ~1.5% of sporadic ALS and in some cases of FTD (Mackenzie et al. 2010). 
Over 50 TARDBP mutations have been linked to ALS, most of which fall within the C-
terminal prion-like domain, suggesting they may affect the aggregation propensity of the 
protein. Clinically, TARDBP mutations are associated with typical, adult onset ALS, and 
there are no significant differences in disease manifestation associated with specific 
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mutations. The identification of TDP-43 pathology and TARDBP mutations suggested 
that age, mutations, and other factors can have a similar effect on TDP-43 behavior, 
which ultimately cause the protein to behave in a pathogenic manner. 
 
TDP-43 structure and function 
 TARDBP, located on human chromosome 1, encodes the highly conserved 
protein TDP-43 of 43 KDa, which is composed of 414 amino acids. The gene contains 6 
exons and encodes 11 mRNAs through alternative splicing whose functions are mostly 
unknown (Wang et al. 2004). TDP-43 is similar in structure and function to many 
heterogeneous nuclear ribonucleoproteins (hnRNPs), enabling its many roles in RNA 
metabolism (Figure 1.2) (Buratti & Baralle 2008; Sun & Chakrabartty 2017). It has an N-
terminal nuclear localization signal and a nuclear export signal within an RNA binding 
domain, allowing it to shuttle between the nucleus and cytoplasm to execute its various 
functions. The two RNA recognition motifs (RRM1 and RRM2) enable TDP-43 to bind to 
(UG)n- and (TG)n- enriched RNA and DNA, respectively (Buratti & Baralle 2001; Ayala 
et al. 2005). The C-terminal domain is glycine rich and structurally disordered, 
resembling the yeast prion-like domain, and work implicates this and other low 
complexity domains in interactions with other RNA binding proteins (Gitler & Shorter 
2011; Buratti et al. 2005; D’Ambrogio et al. 2009; Kato et al. 2012). The C-terminal 
domain is particularly aggregation prone and additionally contains almost all ALS-linked 
TARDBP mutations (Johnson et al. 2007). Together the domain structure of TDP-43 
foreshadows its functions in DNA and RNA metabolism and implicate the low 
complexity domain and protein-protein interactions in TDP-43 toxicity in ALS. 
12 
 
 Like most hnRNPs, TDP-43 is an essential protein that is necessary for cell 
survival, and this is supported by TDP-43 elimination studies. TDP-43 knockout mouse 
embryos die before implantation between embryonic day 3.5 and 6.5, elimination of the 
TDP-43 homolog in Drosophila results in pupal lethality or reduced lifespan, and 
knockdown in zebrafish results in motor axon targeting defects and motor deficits (Wu 
et al. 2010; Sephton et al. 2009; Hazelett et al. 2012; Kabashi et al. 2009). Postnatal 
elimination of TDP-43 results in dramatic loss of body fat and death in 9 days, 
elimination from motor neurons results in motor neuron death, and elimination or 
knockdown in cell culture also led to cell death (Chiang et al. 2010; Wu et al. 2012; 
Iguchi et al. 2013). TDP-43 is robustly expressed ubiquitously from early developmental 
stages and maintains lower expression levels in the nervous system through adulthood 
(Huang et al. 2010; Sephton et al. 2009). Together, these data suggest essential roles 
for TDP-43 in embryonic and postnatal cell survival and function.  
 In addition to a general requirement for TDP-43, a neuronal requirement has also 
been described. TDP-43 is expressed ubiquitously throughout the central nervous 
system and involved in neurite and dendrite outgrowth, motor function, NMJ 
maintenance, and axon targeting (Iguchi et al. 2009; Sephton et al. 2012). At the RNA 
level, TDP-43 regulates many RNAs involved in neuronal development and function, 
which together suggests an important role for TDP-43 in the nervous system (Sephton 
et al. 2011). On a molecular level, TDP-43’s role in embryonic, postnatal, and neuronal 




 TDP-43 regulates gene expression on many levels through its interactions with 
proteins, DNA, and species of RNA. It was first described as a DNA binding protein that 
represses human immunodeficiency virus type 1 gene expression, and it has been 
further implicated as a transcriptional repressor through binding to the SP-10 gene 
(Ignatius et al. 1995; Acharya et al. 2006). TDP-43 has been implicated in transcription 
less concretely through interactions with subunits of a complex that bind to RNA 
polymerase II and initiate transcription and with an exonuclease that is involved in 
transcription termination (Lehner & Sanderson 2004; Sato et al. 2004), however future 
work will be required to determine the specific role of TDP-43 in transcription.  
TDP-43 also binds to RNA, and early work showed that it regulates splicing of 
the human cystic fibrosis transmembrane conductance regulator gene (Buratti et al. 
2001). Subsequently, many direct splicing targets of TDP-43 were identified including 
other splicing factors and its own mRNA (Polymenidou & Lagier-Tourenne 2011; 
Tollervey et al. 2011), and it was shown to interact with other proteins involved in 
splicing (Freibaum et al. 2010). TDP-43 knockdown led to many splicing changes at loci 
in which TDP-43 does not bind (Polymenidou & Lagier-Tourenne 2011), and recently a 
novel role for TDP-43 was identified in the repression of nonconserved cryptic exons in 
a cell type specific manner (Ling et al. 2015). Together, these data suggest TDP-43 
plays a direct role in splicing through interactions with specific mRNAs and an indirect 
role through the regulation of mRNAs that encode splicing factors and interactions with 
proteins. 
 TDP-43 interacts with additional species of RNA that can affect gene expression. 
It is a component of the Drosha complex (Gregory et al. 2004), which is involved in 
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microRNA (miRNA) processing, and its functional role comes from observation of 
dysregulation of many miRNAs upon TDP-43 knockdown (Buratti et al. 2010). It also 
regulates expression of long noncoding RNAs (lncRNAs) whose functions are mostly 
unknown but thought to include transcriptional and post-transcriptional regulation of 
cellular processes. Its interaction with lncRNA NEAT1 suggests a role for TDP-43 in 
assembly of nuclear paraspeckles, which may contribute to transcriptional regulation 
(Tollervey et al. 2011). 
 The interactions between TDP-43 and species of RNA allow TDP-43 to regulate 
RNA stability and localization. TDP-43 binding regions are abundant in the 3’ 
untranslated region (UTR) of genes (Sephton et al. 2011; Colombrita et al. 2012), a 
region known to regulate RNA stability, and TDP-43 has been shown to affect the 
stability of specific RNAs including the low molecular weight neurofilament subunit 
(Strong et al. 2007). TDP-43 also binds to many mRNAs involved in synaptic function 
and is actively transported bidirectionally in axons with other RNA binding proteins and 
specific RNAs, which suggests a role for TDP-43 in localizing mRNA in highly polarized 
cells like neurons and in promoting synaptic plasticity (Alami et al. 2014; Narayanan et 
al. 2013). 
TDP-43 also binds to a region in its own highly conserved 3’ UTR to execute its 
essential role in the regulation of its expression levels in a negative feedback loop, in a 
manner similar to other RNA binding proteins. By one mechanism, the 3’ UTR binding 
promotes RNA instability and exosome mediated degradation and by another promotes 
alternative splicing of an intron within the 3’ UTR, leading to nonsense mediated decay 
(Ayala et al. 2011; Polymenidou & Lagier-Tourenne 2011). Support for this role comes 
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from observation of equivalent TDP-43 levels in the mouse whether TDP-43 is 
expressed in a hemi- or homozygous state, downregulation of endogenous mouse TDP-
43 upon human TDP-43 overexpression, and increased TDP-43 levels in embryonic 
stem cells upon deletion of the 3’ UTR (Stribl et al. 2014; Sephton et al. 2009; Igaz et al. 
2011; Xu et al. 2010). In mice hemizygous for TDP-43, age related motor deficits occur, 
suggesting that aging may impair TDP-43 autoregulation (Kraemer et al. 2010). 
Together these data indicate that TDP-43 is a highly regulated protein, and natural or 
artificial factors affecting TDP-43 autoregulation and expression may be toxic. 
 In addition to regulation at the transcriptional level, TDP-43 also regulates gene 
expression at the translational level. TDP-43 acts as a translational repressor in RNA 
granules within hippocampal dendrites and additionally colocalizes with other RNA 
regulatory proteins in an activity dependent manner (Wang et al. 2008). TDP-43 
associates with translational machinery generally and with stalled ribosomes under 
conditions of cellular stress (Freibaum et al. 2010; Higashi et al. 2013). Two of TDP-43’s 
specific targets have been identified, Map1b and Rac1, which implicate TDP-43 in 
neuronal functions (Godena et al. 2011; Majumder et al. 2012), and identification of 
more targets will further elucidate specific functions of TDP-43. 
 Lastly TDP-43 is involved in the cellular stress response through localization to 
stress granules. Stress granules reversibly form in response to cellular stress such as 
heat, oxidative stress, and glucose deprivation and serve to sequester RNAs and halt 
translation so that the cell can direct energy and resources towards survival. TDP-43 is 
recruited to stress granules upon exposure to various stressors and may affect stress 
granule assembly, morphology, and resulting cell viability (Colombrita et al. 2009; 
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McDonald et al. 2011; Higashi et al. 2013). Stress granule dynamics are mediated by 
reversible interactions between RNA binding proteins in their low complexity domains, 
and through the accumulation of stress these interactions may lead to irreversible 
aggregate formation. 
 In summary, TDP-43 has an essential cellular function that may relate to its 
multifaceted role in the regulation of gene expression. Understanding the role of TDP-43 
in ALS therefore requires understanding how mutations and aging lead to changes in 
TDP-43 behavior and function.  
 
TDP-43 models of ALS 
 In order to dissect TDP-43 mechanisms of neurodegeneration it is first necessary 
to model the age-dependent consequences of modifying TDP-43 expression through 
elimination and mutation. Many groups have generated animal models eliminating TDP-
43 and expressing mutant and wild type forms, and the results and conclusions are 
described below. 
 
TDP-43 knockout models 
 TDP-43 reduction and elimination has been used as a technique to study the 
normal role of TDP-43 and its role in disease. Mice hemizygous for TDP-43 with one 
wild type and one knockout allele maintain the same protein levels as in wild type mice 
due to TDP-43 autoregulation and do not present with a neurodegenerative phenotype 
(Kraemer et al. 2010). Groups have shown that TDP-43 elimination constitutively results 
in early embryonic lethality, establishing a critical role for TDP-43 in development 
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(Sephton et al. 2009; Wu et al. 2010). Postnatal elimination of TDP-43 resulted in rapid 
death and metabolic defects 9 days after TDP-43 elimination, establishing a critical role 
for TDP-43 in postnatal survival (Chiang et al. 2010). Lastly, TDP-43 reduction by 
ubiquitous expression of a silencing microRNA led to paralysis and motor neuron loss in 
the brain and spinal cord, and death at approximately 10 weeks (Yang et al. 2014). 
Interestingly, TDP-43 was not lost in motor neurons themselves, suggesting non-cell 
autonomous contributions to cell death. Elimination of the TDP-43 homolog from 
Drosophila and zebrafish was also toxic, and elimination from C. elegans yielded 
confusing results with increased lifespan in addition to increased sensitivity to stress 
(Wang et al. 2011; Kabashi et al. 2009; Vaccaro et al. 2012; Feiguin et al. 2009). These 
data broadly suggest a neuronal sensitivity to TDP-43 levels and emphasize the toxicity 
of ubiquitous reduction.  
 To overcome the lethality of TDP-43 elimination, a cell type specific elimination 
strategy was used in two studies, which report motor neuron specific elimination of 
TDP-43 using a conditional knockout strategy. Using cre recombinase driven by the 
homeobox transcription factor Hb9 promoter, TDP-43 elimination in motor neurons 
resulted in progressive motor weakness and motor neuron loss, culminating in death at 
10 months (Wu et al. 2012). While the authors suggest motor neuron specificity of the 
Hb9:Cre, previous studies indicate cre is expressed in a wider variety of cells (Hess et 
al. 2007). A different study uses cre driven by the vesicular acetylcholine transporter 
(VAChT) promoter to eliminate TDP-43 in approximately 50% of motor neurons, leading 
to late onset motor deficits and motor neuron loss (Iguchi et al. 2013). Together, these 
studies suggest that TDP-43 is required for long term motor neuron survival, however 
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they do not necessarily implicate TDP-43 loss of function in ALS. The toxicity that 
results from TDP-43 elimination may simply be due to the absence of an essential gene 
for cell survival. 
 
Non-mammalian model systems 
 The advantages of using non-mammalian model systems stem from their ease of 
generation and use, and as a highly conserved protein, TDP-43 seems to behave 
similarly in these model systems as in rodents and humans. 
 A yeast model of TDP-43 proteinopathy found that TDP-43 expression resulted in 
TDP-43 cytoplasmic aggregation, insolubility, and toxicity in a mutation dependent 
manner such that ALS mutations exacerbated the phenotypes (Johnson et al. 2009). 
Additionally, experiments indicated that the C-terminal domain was necessary for 
cytoplasmic aggregation and toxicity, and the C-terminal domain and RNA recognition 
motifs together were sufficient for cytoplasmic aggregation and toxicity (Johnson et al. 
2007; Johnson et al. 2009). An advantage of the yeast model system is the ability to 
rapidly screen for genetic modifiers. Such a screen revealed the homolog of ataxin-2 as 
a TDP-43 modifier, and this led to the identification of intermediate polyglutamine 
expansions in ataxin 2 as a novel risk factor for ALS (Elden et al. 2010). 
 Expression of mutant or wild type TDP-43 in Drosophila, C. elegans, and 
zebrafish resulted in variable mutation- and dose- dependent phenotypes which 
included death, paralysis, movement abnormalities, and axonal defects (Wegorzewska 
& Baloh 2011; Kabashi et al. 2009). TDP-43 pathology was also variable, leading to 
insoluble TDP-43, soluble CTFs, or neither depending on the model, and whether 
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toxicity depends on cytoplasmic localization is still unclear. As with the yeast model, 
these systems have enabled exploration of genetic interactions amongst ALS proteins 
and have implicated a common pathway with TDP-43 and FUS but not SOD1 (Kabashi 
et al. 2011; Wang et al. 2011). 
 
Mammalian model systems 
 Mammalian model systems are often preferred for validating results from non-
mammalian systems and modeling complex diseases like ALS. While the experiments 
are longer, the closer resemblance to humans suggests the systems may be more 
disease relevant. In addition many therapeutics are first tested in mammalian model 
systems before progression to clinical trials, thus effective mammalian model systems 
are necessary for mechanistic analysis and therapeutic identification. Many groups have 
generated mouse models expressing different forms of mutant and wild type TDP-43, 
and they will be described below based on the expression pattern of TDP-43 (Table 
1.2). Additionally, rat and non-human primate models have been generated and they 
will be described at the end. 
 
Ubiquitous TDP-43 overexpression 
 The murine prion promoter (mPrp) allows transgene expression in the central 
nervous system, including in neurons and astrocytes. Three published models use 
mPrp-driven human TDP-43 expression and the results are variable. In the first model, 
mutant TDP-43 at 3-fold endogenous levels led to motor deficits by 13 weeks and death 
by 22 weeks, accompanied by upper and lower motor neuron loss, gliosis, aggregates, 
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and CTFs (Wegorzewska et al. 2009). Another model described a motor phenotype 
resulting from expression of mutant and wild type TDP-43 at 2.5-fold endogenous 
levels, resulting in death by 4-8 weeks, gliosis, aggregation, and CTFs. Importantly, 
decreased expression of mutant TDP-43 resulted in the absence of a phenotype (Xu et 
al. 2010; Xu et al. 2011). A different model described 3-4 fold overexpression leading to 
an expression-level- and mutation- dependent motor phenotype, resulting in premature 
death, gliosis, TDP-43 aggregation, and CTFs (Stallings et al. 2010). 
 One group used recombination mediated cassette exchange to express human 
mutant TDP-43 from the endogenous TDP-43 locus to achieve more physiological 
expression, however absence of the 3’ untranslated region (UTR) led to 3-fold protein 
overexpression (Stribl et al. 2014). Mice displayed mild motor neuron loss and motor 
defects, TDP-43 insolubility and aggregation, and metabolism defects, however the 
motor neuron phenotype was not progressive. The metabolism defects here resemble 
those associated with TDP-43 elimination, and in addition the authors observe 
downregulation of mouse wild type TDP-43. Together these observations suggest the 
phenotype arose as a result of loss of TDP-43 function. The authors did not generate a 
similar wild type control mouse, complicating the interpretation of the results. 
 Perhaps the most promising published TDP-43 model described a mutation-
dependent phenotype with “1-1.5”-fold TDP-43 overexpression (Arnold et al. 2013). 
Closer examination of TDP-43 levels revealed 1.5-3-fold overexpression, with the only 
motor phenotype present upon 3-fold overexpression. Nonetheless, authors described a 
motor phenotype upon expression of TDP-43Q331K but not TDP-43WT or TDP-43M337V, 
accompanied by motor neuron loss and neuromuscular junction defects. Interestingly, 
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absent was TDP-43 mislocalization, aggregation, insolubility, and CTFs. Concerning 
about this model, however, is that the phenotype stopped progressing and stabilized by 
10 months, and only 1 of the mutants led to a phenotype. The authors did not speculate 
about these concerns and thus readers are left wondering about the relevance to ALS. 
 Use of bacterial artificial chromosome (BAC) transgenesis has allowed 
expression of human TDP-43 under the control of its own promoter, and therefore 
expression levels and patterns should more closely mimic those of endogenous TDP-43 
(Swarup et al. 2011). This approach yielded 3-fold overexpression of wild type and 
mutant TDP-43 and resulted in a motor phenotype, gliosis, TDP-43 aggregation, and 
CTFs. Some of these phenotypes were exacerbated with expression of mutant protein. 
 
Neuronal TDP-43 overexpression  
 The Thy1.2 promoter has been used to overexpress wild type and mutant human 
TDP-43 almost exclusively in neurons (Caroni 1997), albeit with line to line variability of 
expression patterns (Feng et al. 2000). In two models, overexpression of wild type TDP-
43 led to an expression-level-dependent motor phenotype, and in some cases 
premature death, motor neuron loss, gliosis, TDP-43 aggregation, and CTFs (Shan et 
al. 2010; Wils et al. 2010). In one report, TARDBP mutation exacerbated pathology 
(Janssens et al. 2013). An unpublished report from Philip Wong’s group described mild 
overexpression of TDP-43 accompanied by a late onset motor neuron phenotype, and 
this phenotype was similar upon expression of mutant or wild type TDP-43 (Tsao et al. 
2012). Additionally, overexpression of CTFs led to age dependent increase in CTFs and 
cognitive decline (Caccamo et al. 2012). 
22 
 
 The most recent published TDP-43 model used the neurofilament heavy chain 
promoter to drive expression of TDP-43 without its nuclear localization signal (TDP-
43ΔNLS) in the brain, spinal cord, and some astrocytes in order to recapitulate the 
cytoplasmic aggregation of TDP-43 present in ALS patients (Walker et al. 2015). 
Authors observe neuronal loss and muscle denervation, motor defects, premature 
death, TDP-43 insolubility, and rare TDP-43 aggregates, and these pathologies were 
reversible upon turning off the transgene. The artificiality of the system, however, 
questions the ALS relevance. The authors expressed a form of TDP-43 that is not 
observed genetically in patients in order to force the cytoplasmic mislocalization and 
aggregation of TDP-43. Moreover, authors did not use overexpression controls upon 
analyzing motor neuron pathology, making it difficult to determine whether it is 
cytoplasmic mislocalization or overexpression itself leading to pathology. Interestingly, 
authors observed rare aggregation despite widespread motor neuron loss thus 
dissociating aggregation from motor neuron pathology. 
 
Forebrain TDP-43 Overexpression 
 The CamKII promoter has been used to overexpress wild type and modified 
mouse and human TDP-43 in the cortex and hippocampus. Overexpression of mouse 
TDP-43 led to behavioral and motor deficits, premature death, gliosis, motor neuron 
loss, TDP-43 aggregation, and CTFs (Tsai et al. 2010). Another model observed a 
motor phenotype, premature death, neuronal loss, gliosis, and CTFs upon 
overexpression of human TDP-43ΔNLS (Igaz et al. 2011). In comparison, overexpression 
of wild type led to a similar phenotype with later onset, however as expression was 
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almost 8 fold higher in TDP-43ΔNLS mice, the phenotype may be more expression-level- 
rather than TDP-43ΔNLS- dependent. Lastly, another group reported expression-level-
dependent premature death, neuronal loss, and TDP-43 aggregation upon 
overexpression of wild type human TDP-43 (Cannon et al. 2012). Toxicity of mutant 
TDP-43 was also expression-level-dependent such that high overexpression led to brain 
size abnormalities, however low expression led to the absence of a phenotype. 
Interestingly, the toxicity was completely independent of protein aggregation (D’Alton et 
al. 2014). 
 
TDP-43 overexpression in the rat 
 Overexpression of human TDP-43 in the rat using a BAC transgenesis approach 
led to a motor phenotype and premature death that was absent with wild type 
overexpression (Zhou et al. 2010). As a result, the authors generated tet-inducible 
transgenics expressing mutant TDP-43 in neurons under the control of a CMV 
promoter, leading to rapid development of a motor phenotype, premature death, gliosis, 
neuronal loss and rare TDP-43 aggregation. Motor neuron specific expression resulted 
in a more pronounced motor neuron phenotype, however with less TDP-43 aggregation 
(Huang et al. 2012). Tet-inducible transgenics were compared to nontransenic controls 
instead of wild type overexpressors, thus questioning whether experiments were 
properly controlled. 
 
TDP-43 overexpression in a non-human primate 
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 Viral overexpression of human wild type TDP-43 in monkeys led to progressive 
motor weakness, TDP-43 mislocalization, and motor neuron loss (Uchida et al. 2012). 
Comparison to a rat overexpression system revealed that mislocalization was not 
required for presentation of the phenotype. TDP-43 was overexpressed 20 times higher 
than endogenous levels in both systems. 
 
 Animal models have emerged as an important to tool with which to study the 
consequences of genetic mutations, elucidate disease mechanisms, and test potential 
therapeutics. While animal models changed the landscape of ALS research, their 
discoveries have not yet translated into clinical success. Close inspection of the 
mammalian models described above suggests many caveats associated with these 
systems. 
These models highlight the importance of TDP-43 levels to its role in the cell: 
both elimination and overexpression of mutant or wild type forms are toxic. While TDP-
43 is normally able to autoregulate through binding to its 3’ UTR, this ability is 
eliminated upon expression of TDP-43 from cDNA in the aforementioned transgenics 
without key elements of the 3’ UTR that are involved in autoregulation and mRNA 
processing (Stribl et al. 2014). This caveat prevents meaningful analysis of the effects of 
TARDBP mutations in these systems. Indeed, the 3’ UTR has been recently shown to 
play an important role in translation and protein-protein interactions in addition to RNA 
stability (Mayr 2016). Thus to model the age-dependent effects of TARDBP mutations 
on long term motor neuron survival a less artificial approach is required in which TDP-
43 expression levels and patterns are not disrupted. 
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 We also observe an interesting dissociation in some of these model systems 
between TDP-43 aggregation and neurodegeneration. While aggregation of TDP-43 is 
present in some model systems, it is notably absent or minimal in others in which 
neurodegeneration is still observed, in some cases dramatically (Arnold et al. 2013; 
D’Alton et al. 2014; Walker et al. 2015). This opens the possibility that aggregation may 
not be driving neurodegeneration but either acting as an amplifier, an innocent 
bystander, or a protective event late in the disease and thus when present in model 
systems may primarily be a product of protein overexpression. 
 Taken together, these data suggest the importance of observing the effects of 
TARDBP mutations in a physiological context in which we can determine the effects of 
the mutations on the normal properties of the protein and on age-dependent motor 
neuron health. 
 
TDP-43 mechanisms of neurodegeneration 
 TDP-43 is an essential cellular protein with many described functions, and 
additionally it aggregates in ALS. These data suggest two non-mutually-exclusive 
general mechanisms by which TDP-43 might lead to neurodegeneration: loss of 
function and gain of function. 
TARDBP mutations and aging may have the effect of interfering with normal 
TDP-43 function in the cell, and this loss of TDP-43 function may lead to motor neuron 
disease. Support for this hypothesis comes from observations of TDP-43’s functions, 
the effects of ALS-mutations on protein function, and observations from ALS patients. 
TDP-43 has a role in tightly controlling its own expression through an autoregulatory 
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mechanism involving RNA transcription, splicing and 3′ end processing, and loss of this 
function results in toxic overexpression. TDP-43 affects splicing of cryptic exons, which 
are shown to be dysregulated in ALS patients. TDP-43 also has critical roles in survival, 
as elimination embryonically or postnatally in the mouse results in lethality. This lethality 
may indicate a role for TDP-43 function in ALS, however it may also simply result from 
the absence of an essential gene. Work in zebrafish model systems indicates that 
mutant TDP-43 cannot fully rescue the defects associated with TDP-43 homolog 
elimination, suggesting that the protein does not retain full function (Kabashi et al. 
2009). Other observations from patients indicate nuclear exclusion and cytoplasmic 
aggregation of TDP-43 are hallmarks of ALS pathology, suggesting absence from the 
nucleus and/or sequestration in cytoplasmic aggregates may lead to TDP-43 loss of 
function. Despite this evidence, however, whether TDP-43 loss-of-function causes 
neurodegeneration in ALS remains uncertain. 
Alternatively, or in addition, the mutations and aging may not impair normal 
protein function but may instead confer a gain of function toxicity on TDP-43, which may 
relate to the formation of abnormal assemblies. Observations from patients indicate that 
TDP-43 is hyperphosphorylated, ubiquitinated, cleaved into CTFs, and mislocalized to 
the cytoplasm, and the toxic gain of function may relate to any of these properties. TDP-
43 aggregation is thought to arise from the structurally disordered C-terminal domain 
due to its low complexity and resemblance to yeast prion domains, and this particularly 
aggregation prone region is a primary component of ALS-associated TDP-43 inclusions 
(Sun & Chakrabartty, 2017). ALS mutations cluster in the C-terminal domain and 
studies suggest that these mutations may increase the aggregation propensity of the 
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protein and disrupt the normal interactions between TDP-43 and components of 
ribonuclear granules that regulate a variety of cellular processes, thus contributing to 
the formation of abnormal assemblies and neurotoxicity of TDP-43 (Conicella et al. 
2016; Gopal et al. 2017). Additionally, the increased propensity to aggregate may lead 
to TDP-43 sequestration and a secondary loss of TDP-43 function. The near-ubiquitous 
TDP-43 pathology suggests aggregates play a role, however the absence of 
aggregation in many motor neuron disease models complicates our understanding of 
the importance of aggregation. 
Differentiating between these disease mechanisms is critical for the development 
of effective therapeutics, however the absence of genetically faithful animal models in 
combination with the complexity of TDP-43 pathology has impeded clear understanding 
of TDP-43-mediated neurodegeneration. Work in this thesis will address these problems 
in order to better understand the consequences of TARDBP mutations. 
 
1.5 FUS in ALS 
 Mutations in Fused in Sarcoma (FUS, also known as Translated in Liposarcoma-
TLS) were linked to ALS in 2009 (Kwiatkowski et al. 2009; Vance et al. 2009). As 
described below, FUS is both structurally and functionally related to TDP-43, suggesting 
overlapping disease mechanisms involving RNA metabolism. 
 
FUS mutations and pathology 
 Over 70 mutations in FUS are linked to ALS, accounting for ~4% of familial ALS 
and less than 1% of sporadic ALS (Deng et al. 2014). Many of the mutations fall in the 
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C-terminal nuclear localization signal (NLS), causing FUS to mislocalize from the 
nucleus into the cytoplasm (Figure 1.4). Many mutations that are not in the NLS fall in 
the N-terminal prion-like domain and, similar to the case of TDP-43, increase the 
aggregation propensity of FUS (Nomura et al. 2014). Unlike TARDBP mutations, certain 
FUS mutations, such as P525L, are associated with increased pathogenicity and cause 
some of the only forms of juvenile onset, aggressive cases of ALS, while others cause 
the typical adult onset form of the disease (Deng et al. 2014). Interestingly, the 
pathogenicity of the mutation correlates with the degree of cytoplasmic mislocalization 
of FUS (Dormann et al. 2010). 
 On a pathological level, patients with FUS mutations have insoluble FUS 
aggregates in the cytoplasm of neurons and glia, sometimes accompanied by nuclear 
clearance of FUS (Rademakers et al. 2011). These aggregates are ubiquitinated and 
contain p62 and stress granule markers but interestingly do not contain TDP-43 
(Dormann et al. 2010; Vance et al. 2009). Some reports indicate the presence of FUS in 
aggregates in sporadic ALS patients, however others suggest FUS only aggregates 
when FUS mutations are present (Vance et al. 2009; Deng et al. 2010). Therefore the 
relevance of FUS to sporadic ALS remains uncertain. 
 Like TDP-43, FUS is also connected to FTD and other neurodegenerative 
diseases. FUS mutations themselves do not seem to solely cause FTD but are found in 
some ALS patients that also present with FTD, and in addition FUS aggregates are 
found in a subset of FTD cases (Deng et al. 2014). These patients generally present 
with early onset, sporadic FTD without motor features, and the aggregates have 
similarities and differences to those found in ALS. Like in ALS, in FTD FUS aggregates 
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are neuronal, and glial, insoluble, TDP-43 negative, and ubiquitin positive. Unlike in 
ALS, in FTD FUS aggregates with other proteins from the FET family and nuclear 
import protein Transportin (Neumann et al. 2011; Neumann et al. 2012). FUS 
aggregates have also been found in other diseases such as Huntingon’s and 
spinocerebellar ataxias (Lagier-Tourenne et al. 2010; Lattante et al. 2013). Together, 
these data suggest that FUS, like TDP-43, plays a broad role in neurodegeneration, 
however FUS may act through distinct, disease-specific mechanisms. 
 
FUS structure and function 
 FUS, located on human chromosome 16, encodes the highly conserved FET 
family protein FUS of 75 KDa, which is composed of 526 amino acids. Like TDP-43, 
FUS is similar in structure and function to many other hnRNPs (Figure 1.4). It has an N-
terminal low complexity domain that mediates self-assembly and interactions with other 
proteins and a C-terminal NLS that facilitates import into the nucleus (Schwartz et al. 
2013; Kato et al. 2012; Dormann et al. 2010). In between are RRM, RGG, and zinc 
finger domains that bind RNA, DNA, and proteins to mediate aspects of FUS function. 
FUS was initially identified as part of a fusion protein in tumors in which the FUS 
sequence acted as a transcriptional activator for transcription factor CHOP (Crozat et al. 
1993; Rabbitts et al. 1993), and since, many roles in regulating gene expression have 
been ascribed to FUS (Figure 1.5). 
 Like TDP-43 and other hnRNPs, FUS is a predominantly nuclear and 
ubiquitously expressed DNA and RNA binding protein that affects gene expression on 
many levels. On a transcriptional level, FUS binds to chromatin to initiate transcription 
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(Yang et al. 2014) and binds to and regulates phosphorylation of RNA polymerase II to 
enable elongation (Schwartz et al. 2012). In addition it binds to transcription factors, 
such as Spi-1 and others, to both activate and repress transcription (Hallier et al. 1998; 
Uranishi et al. 2001). 
 FUS is also involved in mRNA processing through interactions with proteins and 
many species of RNA. FUS binds to RNA, primarily at introns, and FUS elimination 
alters the splicing and expression of many mRNAs (Lagier-Tourenne et al. 2012; Rogelj 
et al. 2012). FUS is involved in the maintenance and formation of gems, subnuclear 
structures with roles in RNA processing, and has been reported to bind to components 
of the spliceosome and other hnRNPs (Yamazaki et al. 2012; Behzadnia et al. 2007; 
Blokhuis et al. 2016; Wang et al. 2015; Kamelgarn et al. 2016). Together, these data 
implicate FUS in mRNA splicing directly by interacting with RNA and indirectly by 
interacting with other RNA binding proteins. FUS also interacts with the Drosha 
complex, miRNAs, and lncRNAs, and regulates circular RNA biogenesis, which 
ultimately influence gene expression (Gregory et al. 2004; Modigliani et al. 2014; Lagier-
Tourenne et al. 2012; Errichelli et al. 2017). 
 Like TDP-43, FUS has an important role in regulating its own protein levels 
through a negative feedback loop. Its autoregulation may involve miRNA suppression of 
FUS or nonsense mediated decay as a result of exon skipping (Modigliani et al. 2014; 
Zhou et al. 2013). By whichever mechanism, it seems FUS expression levels are tightly 
controlled. 
 FUS also shuttles from the nucleus into the cytoplasm where it affects RNA 
stability and localization and the cell’s stress response. Evidence in support of its role in 
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stability comes from its interaction with RNA at the 3’ UTR and other factors controlling 
3’ end processing, and from specific transcripts whose stability FUS regulates 
(Colombrita et al. 2012; Lagier-Tourenne et al. 2012; Rogelj et al. 2012; Udagawa et al. 
2015). FUS also associates with RNA granules that can affect gene expression in a 
context-dependent manner. Activity dependent localization of FUS with RNAs to the 
synapse can regulate local translation and spine remodeling (Fujii et al. 2005; Fujii & 
Takumi 2005), while localization to stress granules ensures that a cell is focused 
primarily on survival in response to exogenous stressors (Andersson et al. 2008). 
 In addition to its RNA processing functions, FUS is involved in the cell’s DNA 
damage response. FUS binds both single and double stranded DNA and is recruited to 
DNA upon lesion (Baechtold et al. 1999). It interacts with other DNA damage proteins 
such as HDAC1 at sites of DNA damage and promotes homologous recombination 
during break repair (Wang et al. 2013). In addition, FUS knockout mice show genomic 
instability, chromosomal breakage, and increased sensitivity to radiation (Hicks et al. 
2000; Kuroda et al. 2000). 
Lastly, FUS has important functions in development and neurons. Its elimination 
resulted in lethality in Drosophila and embryonic lethality with immune defects in the 
mouse that was dependent on the mouse genetic background, and knockdown in 
zebrafish led to motor deficits (Wang et al. 2011; Hicks et al. 2000; Kuroda et al. 2000; 
Kabashi et al. 2009; Kabashi et al. 2011). In addition, FUS elimination resulted in 
abnormal dendritic spine morphology and density, suggesting a role for FUS in synaptic 
function (Fujii et al. 2005). 
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In summary, FUS has many overlapping roles with TDP-43 in the regulation of 
gene expression and in development and function. Effective animal modeling has 
further elucidated the role of FUS function in long term motor neuron survival and ALS. 
 
FUS animal models 
 Many models expressing human wild type and mutant forms of FUS have been 
generated and analyzed in order to determine the role of FUS in ALS. Similar to TDP-43 
models, overexpression and transgenic models have yielded confusing results due to 
the toxicity of overexpression of wild type FUS and the variability of the phenotypes. 
Recent work, however, established two different and effective mouse models of FUS-
ALS that lead to similar conclusions about disease mechanisms. 
 
FUS expression from the MAPT locus (Sharma et al. 2016) 
 Work from our lab established a series of mice expressing human wild type or 
mutant FUS in a controlled manner from the MAPT genetic locus to avoid 
overexpression and insertion effects. Modest FUS expression led to mutation 
dependent motor neuron loss, NMJ defects, FUS mislocalization, and motor defects 
with cell autonomous and cell non-autonomous contributions to the phenotype. Notably 
absent were cytoplasmic FUS inclusions, such as those observed in end stages of 
disease in patients. Interestingly, phenotypic severity correlated with clinical severity of 
the mutations, and the expression of wild type FUS did not lead to a phenotype, 
suggesting that the model faithfully reproduces the effects of FUS mutations. 
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 Additional experiments assessed the mechanism by which FUS mutations cause 
ALS. As described previously with respect to TDP-43, mutations may cause 
neurodegeneration by a loss of the normal FUS function, or the mutations may lead to a 
gain of toxic function. In order to distinguish between these mechanisms, authors asked 
whether FUS function was required for long term motor neuron survival. While FUS is 
an essential protein in development, its postnatal requirement is unknown. Surprisingly, 
postnatal loss of FUS did not cause any motor neuron pathology, suggesting that FUS 
is not required for long term motor neuron survival and loss of FUS function is 
insufficient to cause ALS. 
 
FUS knock-in models 
 Insertion of FUS mutations into the endogenous mouse FUS genetic locus is an 
effective strategy to overcome the toxicity associated with overexpression and the 
random insertion in typical transgenic approaches and has the advantage of authentic 
expression of mutant protein. Insertion of a cre-dependent truncation mutation, modeled 
after a case of sporadic ALS (DeJesus-Hernandez et al. 2010), led to FUS cytoplasmic 
mislocalization and perinatal lethality of homozygotes in a similar manner to FUS 
knockout animals (Scekic-Zahirovic et al. 2016; Scekic-Zahirovic et al. 2017). However, 
unlike FUS knockout animals, knock-in homozygotes had motor neuron loss and knock-
in heterozygotes presented with an age-dependent, progressive motor neuron 
phenotype resembling ALS. In addition, both cell autonomous and cell-non autonomous 
expression of mutant FUS contributed to the phenotype. Together, these data 
suggested that the mislocalized FUS leads to motor neuron death through a toxic gain 
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of function, and the absence of FUS inclusions in these mice suggest aggregation is not 
a necessary event. Similar unpublished work from our lab has led to the same 
conclusions. FUS knock-in mice display dose-dependent toxicity upon comparison of 
hemizygous and homozygous mutants, suggesting that the mutants are associated with 
a toxic gain of function (Drs. Alexander Lyashchenko & Bea Blanco, personal 
communication). 
  
 These animal models demonstrate the advantages of expression of mutant 
protein in a controlled, stereotyped, and physiologically relevant manner. Both models 
report a similar progressive phenotype without FUS aggregation and with involvement 
of motor neurons and other cell types, and both lead to the conclusion that the 
mutations are associated with a gain of function toxicity. 
 
FUS mechanisms of neurodegeneration 
 Models described above suggest FUS mutations are associated with a gain of 
function toxicity and importantly, that aggregation is not a necessary component of 
motor neuron loss.  
 Recent work implicates the low complexity domain of specific RNA binding 
proteins including FUS as a mediator of toxicity in ALS. Low complexity domains, or 
regions with little diversity in amino acid composition, are enriched in DNA and RNA 
binding proteins and may have an important role in regulating gene expression (Kato et 
al. 2012; Han et al. 2012). The low complexity domain mediates the formation of RNA 
granules, membrane-less organelles involved in spatially and temporally localizing 
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proteins and RNA within in the cell. RNA granules are dynamic such that proteins are 
exchanged freely between the granules and the cytoplasm, causing a context-
dependent phase separation into liquid compartments, somewhat like oil and vinegar. 
Certain factors such as protein and salt concentration, temperature, and RNA can drive 
the phase separation and the formation of RNA granules (Guo & Shorter 2015). These 
domains, however, are also prone to cause aberrant protein-protein interactions and 
protein aggregation. The prevalence of the low complexity domain in ALS proteins in 
combination with the dysregulation of RNA as an emerging theme suggested their 
mechanistic role in ALS.  
 Subsequent work showed that ALS-mutations in a number of genes alter the 
dynamics within these granules to promote phase separation and polymerization. Two 
groups showed FUS mutations in the low complexity domain and in the nuclear 
localization signal promote the polymerization of FUS into a solid state from a liquid 
state in a protein concentration-, temperature- and time- dependent manner (Patel et al. 
2015), and this polymerization can ultimately become irreversible (Murakami et al. 
2012). Additionally ALS-causal mutations in heterogeneous nuclear ribonucleoprotein 
A1 (hnRNP A1) accelerated hnRNP A1 fibrillization in a concentration-dependent 
manner, and resulting amyloid-like fibrils could then cross-seed fibrillization of wild type 
protein (Kim et al. 2013; Molliex et al. 2015). Importantly, this work dissociated 
fibrillization and phase separation, as hnRNP A1 can fibrillize without phase separating, 
and non-fibrillizing mutants can phase separate (Molliex et al. 2015; Lin et al. 2015). 
Recent work also showed that ALS mutations in TARDBP cause granules to become 
less mobile, more viscous, and disrupt self-interaction, though unclear in this work was 
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whether mutations promote TDP-43 polymerization (Conicella et al. 2016; Gopal et al. 
2017). Lastly, there is accumulating evidence that C9orf72-repeat-expansion-derived 
dipeptide repeats, especially those containing arginine, phase separate into membrane-
less organelles with other proteins containing low complexity domains and possibly 
disrupt RNA granule dynamics as a result (Boeynaems et al. 2017; Lee et al. 2016; Lin 
et al. 2016). 
 Together, these data suggest that ALS mutations in FUS and other genes can 
alter phase separation of RNA binding proteins and therefore RNA granule dynamics. 
How and whether these changes lead to motor neuron degeneration is still unclear, 
necessitating further research into the precise gain of function mechanisms associated 
with FUS mutations. 
 
1.6 Summary and aims of this thesis 
 The importance of RNA binding proteins in ALS has become clear through 
observation of near-ubiquitous TDP-43 aggregates, mutations in TARDBP, FUS, and 
other RNA binding proteins, and the ALS-causal hexanucleotide repeat expansion in 
C9orf72. Additionally, the structural and functional similarities between TDP-43 and 
FUS suggest that they may lead to overlapping disease mechanisms, however these 
mechanisms have yet to be identified. 
 The generation of a faithful animal model of ALS as a result of FUS mutations 
permits further inquiry into gain of toxic function disease mechanisms, and I hypothesize 
that these mechanisms relate to aberrant protein-protein interactions. Therefore, in 
Chapter 2, I will determine the differences in protein-protein interactions associated with 
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FUS mutations in the mouse model of ALS and subsequently determine whether these 
interactions may be mechanistically relevant. I will then describe experiments to 
determine the functional role of a candidate FUS-interactor in both motor neuron health 
and disease. 
 A barrier to understanding TDP-43-dependent mechanisms of motor neuron 
disease is the absence of a faithful genetic model. Therefore, in Chapter 3, I will present 
the generation of a novel TDP-43 knock-in model in which ALS-causal mutations were 
inserted directly into the mouse endogenous TARDBP genetic locus. I will then describe 
experiments to determine the consequences of these mutations on the normal function 
of the protein and on long term motor neuron survival. 
 In Chapter 4 I will draw conclusions from the work presented in this thesis, and in 
Chapter 5 I will describe experimental methods and procedures used in the completion 
















Figure 1.1: Overview of proposed neurotoxic mechanisms in SOD1 mediated ALS. 







Figure 1.2: TDP-43 domain structure and ALS mutations. 
TDP-43 contains a nuclear localization signal (L) within the N-terminal domain (NTD), 
nuclear export signal (E), 2 RNA recognition motifs (RRM1 & RRM2), and a low 
complexity C-terminal domain (CTD). Mutations are primarily found in the CTD. 






Figure 1.3: TDP-43 functions in RNA metabolism. 
TDP-43 regulates many aspects of RNA processing through interactions with different 
species of RNA and proteins. Boxes indicate RNA targets that have been validated 
experimentally. Consequences of stress granule formation, such as aggregation and 






Figure 1.4: FUS domain structure and ALS mutations. 
FUS has 15 exons (gray), encoding a protein of 526 amino acids. It has an N-terminal 
low complexity domain (QGSY-region), 3 RGG motifs, an RNA recognition motif, 
nuclear export (E) and import (L) signals, and a zing finger domain (ZnF). ALS 
mutations are located in most domains, but in particular within the nuclear localization 





Figure 1.5: FUS functions in DNA and RNA metabolism. 
FUS regulates many aspects of DNA and RNA processing through interactions with 
different species of RNA, DNA, and proteins. Boxes indicate RNA targets that have 
been validated experimentally. Consequences of stress granule formation, such as 







C9orf72 Toxic RNA and/or dipeptide aggregation 
FUS DNA/RNA metabolism 
EWSR1 DNA/RNA metabolism 
TARDBP DNA/RNA metabolism 
SETX DNA/RNA metabolism 
MATR3 DNA/RNA metabolism 
TAF15 DNA/RNA metabolism 
HNRNPA1 DNA/RNA metabolism 
HNRNPA2B1 DNA/RNA metabolism 
ANG DNA/RNA metabolism 
GLE1 DNA/RNA metabolism 






TBK1 Autophagy, inflammation 
FIG4 Intracellular trafficking 
ALS2 Intracellular trafficking 
VAPB Intracellular trafficking 




SIGMAR1 Endoplasmic reticulum lipid rafts 
ERLIN2 Endoplasmic reticulum lipid rafts 
DAO Excitotoxicity 
SOD1 Enzyme, toxic aggregation 
CHCHD10 Mitochondrial function 
ERBB4 Dysregulation of neuregulin-ErB4 pathway 
ARHGEF28 Interaction with NEFL 
PNPLA6 Neurite outgrowth and process elongation 
 
Table 1.1: Mutations in genes of diverse functions cause ALS. 











































































































































































mPrp A315T 3 ++ - A ND Y 0 20% Y 90 154 gait 
Wegorzewska et al. 
2009 
mPrp A315T 3 + + ND ND - 20% 0 Y ND ND - 
Herdewyn et al. 
2014 
mPrp WT 3 ND ND D ND Y 0 ND Y ND >330 - Stallings et al. 2010 
mPrp A315T 4 - ++ A ++ Y 0 ND Y ND 75 weakness, gait Stallings et al. 2010 
mPrp WT 2.5 + ++ D ++ Y ND 0 Y 21 45 clasp, tremors, gait Xu et al. 2010 
mPrp M337V 2.7 + ++ D +++ Y ND 0 Y 21 30 clasp, tremors, gait Xu et al. 2011 
mPrp WT 1 - - - - - 0 0 Y NA - - Arnold et al. 2013 
mPrp M337V 1 - - - - - 0 0 Y 300 - rotarod Arnold et al. 2013 
mPrp Q331K 1.5 - - - - - 30% 35% Y 90 - tremors, weakness Arnold et al. 2013 
endogenous A315T 3 ++ ++ A - - ND 10% ND 90 - gait Stribl et al. 2014 
Thy 1.2 WT 2 ++ ++ D + Y ND 25% Y 20 <30 paralysis, clasp Wils et al. 2010 
Thy 1.2 M337V 1.8 ++ ++ D ++ Y ND Y Y 12 17 clasp, tremors, gait 
Janssens et al. 
2013 
Thy 1.2 WT 3.6 - ++ D ND - 0 ND Y 16 - clasp, tremors, gait Shan et al. 2010 
Thy 1.2 
25 kDa 
CTF 4.7 - - - - Y ND ND ND - - - 
Caccamo et al. 
2012 
CamKII (i) WT 3 ND ++ D ++ Y ND Y Y ND 60 ND Cannon et al. 2012 
CamKII (i, 
P21) WT 3 ND ++ A ++ Y ND Y Y ND >360 ND Cannon et al. 2012 
CamKII mouse WT 2 ++ ++ A - Y ND 25% Y 180 495 clasp, rotarod Tsai et al. 2010 
CamKII (i) WT 0.8 - + - + - ND 20% Y 75 ND clasp Igaz et al. 2011 
CamKII (i) ΔNLS 7.9 +++ + A + - ND 50% Y 7 180 clasp Igaz et al. 2011 
BAC WT 3 ++ ++ A ND - 5% 0 Y 294 ND rotarod Swarup et al. 2011 
BAC A315T 3 +++ +++ A ND Y ND 0 Y 266 ND rotarod Swarup et al. 2011 
BAC G348C 3 +++ +++ A ND Y 10% 0 Y 252 ND rotarod Swarup et al. 2011 
NEFH (i) ΔNLS >10 ++ +++ A +++ - 60% 50% Y 14 72 
clasp, tremors, 
rotarod Walker et al. 2015 
NEFH (i) WT ND - - ND + ND ND ND ND ND ND ND Walker et al. 2015 
NA 
constitutive 
KO             ND ND ND ND - - Wu et al. 2009 
NA 
constitutive 
KO             ND ND ND ND E6.5 - Sephton et al. 2010 
NA 
constitutive 
KO             ND ND ND ND E7.5 - Kraemer et al. 2010 
NA 
conditional 
KO             ND ND ND ND 9 - Chiang et al. 2010 
Hb9-Cre 
conditional 
KO             ND 40% Y 100 300 rotarod, kyphosis Wu et al. 2012 
VaChT-Cre 
conditional 




BAC WT ND ++ - D D Y ND 0 - NA >200 - Zhou et al. 2010 
BAC M337V ND ND ND ND ND ND ND Y ND 15 20 weakness, paralysis Zhou et al. 2010 
CMV (i) M337V ND ++ + D D Y 40% 12% Y 40 55 weakness, paralysis Zhou et al. 2010 
NEF (i) M337V 2 ND - A ND ND 0 20% ND 14 ND weakness, paralysis Huang et al. 2012 
ChAT (i) M337V 3.5 ++ - A ND ND 0 60% Y 7 12 weakness, paralysis Huang et al. 2012 
Table 1.2: TDP-43 rodent models. 
Levels are expressed as fold change compared to endogenous mouse TDP-43 
expression levels. “TDP-43 protein” refers to the human protein unless noted. NA – not 
applicable, ND – not described, Y – yes, dash indicates absence, (i) – inducible system, 
rating system ranges from + (rarely seen) to +++ (frequently seen). A indicates 
presence of the molecular phenotype in aggregates, and D indicates diffuse staining. 
Adapted from Lehrer, H. (2015). “Investigating the role of the RNA binding protein TDP-




Chapter 2: Gain of function mechanisms of FUS toxicity 
 
2.1 Introduction 
FUS mutations are associated with a gain of function toxicity and importantly, 
aggregation is not a necessary component of resulting toxicity. Therefore we focus on 
three differences between mutant and wild type FUS in ALS. 
 First, mislocalization seems to be an essential component of disease. Mutations 
cause the protein to mislocalize from the nucleus to the cytoplasm in animal models, 
recapitulating a key feature of human pathology. Importantly, the degree of 
mislocalization seems to correlate with the severity of the disease clinically (Dormann et 
al. 2010), suggesting it is mechanistically relevant. 
 Second, unpublished work from our lab suggests that FUS mutations cause the 
protein to adopt an abnormal protein conformation. Wild type FUS is recognized by FUS 
antibodies that do not recognize mutant FUS, and the reverse is also true (Drs. Alex 
Lyashchenko and Bea Blanco, personal communication). This indicates that the 
mutations alter protein folding and cause different epitopes to be exposed, leading to an 
altered protein conformation 
 Third, accumulating work indicates that FUS mutations affect its interactions 
within RNA granules with other proteins containing low complexity domains. Studies 
recapitulating the formation of RNA granules in a cell-free environment identified a 
biological role for the low complexity domain in reversibly forming RNA granules by 
interacting with RNA and other RNA binding proteins (Kato et al. 2012). Subsequent 
work showed that ALS-mutations in a number of genes, including FUS, alter the 
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dynamics within these granules to promote liquid-liquid phase separation and 
polymerization. FUS mutations in the low complexity domain and in the nuclear 
localization signal promote the polymerization of FUS into a solid state from a liquid 
state in a protein concentration-, temperature- and time- dependent manner, and this 
polymerization can ultimately become irreversible (Patel et al. 2015; Murakami et al. 
2012). 
 Together, these observations indicate that mutations affect the interactions 
between FUS and other cellular proteins due to compartmental and conformational 
differences, and as a protein’s role in the cell is in large part determined by the proteins 
with which it interacts, I hypothesize that changes in protein-protein interactions are a 





 2.2 Results 
 
Mutant FUS protein interactors identified by mass spectrometry 
 Observed differences between mutant and wild type (WT) FUS, such as protein 
localization, protein conformation, and behavior in membrane-less structures, may 
cause mutant and WT FUS to interact with different proteins inside the cell, and we 
hypothesized that changes in protein-protein interactions as a result of FUS mutations 
are a proximal event in mutation-associated toxicity. Thus to identify gain of function 
mechanisms of FUS toxicity it is first necessary to identify changes in protein-protein 
interactions as a result of FUS mutations. 
 In order to identify FUS-interacting proteins that may have mechanistic 
relevance, we used the novel animal model of FUS-ALS generated in the Shneider lab 
in which mutant and wild type myc-tagged hFUS cDNA was expressed from the MAPT 
genetic locus (Sharma et al. 2016). Importantly, a clinically severe P525L-mutation 
resulted in more severe motor neuron (MN) pathology in comparison to a clinically 
typical R521C-mutation, and expression of hFUSWT did not result in any MN pathology. 
We co-immunoprecipitated hFUSWT or hFUSP525L from the spinal cord of P90 animals, 
an age at which MN pathology is evident, and used a myc antibody so that only hFUS 
and not endogenous mouse FUS would be immunoprecipitated (Fig. 2.1A). To control 
for non-specific interactions between the antibody or beads and the protein lysate, we 
used a WT C57BL/6J non-myc-expressing mouse as a control. Upon co-
immunoprecipitation, we visualized hFUS interacting proteins using SDS-PAGE 
followed by a silver stain. In comparison to the WT negative control, many proteins were 
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co-immunoprecipitated from hFUS-expressing spinal cord, and interestingly differences 
between hFUSWT and hFUSP525L were also apparent (Fig. 2.1B). Specifically, many 
proteins seemed to interact with mutant, but not wild type hFUS. Thus with confirmation 
of differences in protein-protein interactions, we used mass spectrometry (MS) to 
identify the proteins bound to hFUS. 
 By MS we identified 22 proteins that interact with hFUSP525L (Table 2.1). Likely 
due to differences in protein levels between hFUSWT and hFUSmutant (Fig. 2.1C), there 
was insufficient quantity of hFUS immunoprecipitate to identify interactions by MS with 
hFUSWT above the C57BL/6J background. Previous work established that differences in 
protein levels were a consequence of the effect of mutations on protein stability, as RNA 
levels are equivalent across mutant mouse lines despite differences at the protein level 
(Sharma et al. 2016). Nevertheless, we proceeded to validate MS-identified interactions 
with hFUSP525L and test the presence of the interaction with hFUSR521C and hFUSWT. 
 
FUS interactions are mutation dependent 
 Upon testing 8 MS-identified interactions with hFUSP525L, we found that all co-
immunoprecipitated (Fig. 2.1C): hnRNP U, SFPQ, Caprin1, hnRNP R, hnRNP Q, 
hnRNP K, Ddx1, and endogenous mouse FUS. Interestingly, we found that the proteins 
also interacted with hFUSR521C but not hFUSWT, and that the strength of the interaction 
correlated with the severity of the mutation: interactors were more abundant upon co-
immunoprecipitation with the clinically-severe P525L mutant than the clinically-typical 
R521C mutant. Important to note is that the strength of the interaction also seems to 
correlate with the protein levels, suggesting that the aberrant interactions may simply be 
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a result of increased protein stability. However, as the increased protein levels and 
stability result from the mutations found in ALS patients, the aberrant interactions may 
indeed indicate changes in protein-protein homeostasis in patients and may therefore 
be mechanistically relevant. 
 
FUS-hnRNP U interaction is RNA-independent 
 The most abundant mutant-FUS interactor was RNA-binding protein 
heterogenous nuclear ribonucleoprotein U (hnRNP U). HnRNP U has documented roles 
in neurological deficits such as seizure and intellectual disability (Thierry et al. 2012) 
and importantly has previously been connected to ALS. HnRNP U was shown to bind in 
an ALS-mutation-dependent manner to Ubiquilin-2 (Gilpin et al. 2015) and bind in an 
RNA-dependent manner to TDP-43 (Suzuki et al. 2015). In addition, hnRNP U 
expression modulated TDP-43 toxicity (Suzuki et al. 2015). Thus for the relevance to 
neurological deficits and ALS, we identified hnRNP U as a candidate mediator of 
mutant-FUS toxicity. 
 We next wanted to reciprocally validate the interaction between hnRNP U and 
mutant-FUS, and so we performed a co-immunoprecipitation with an hnRNP U antibody 
and found that we selectively precipitate mutant-FUS (Fig. 2.1D). Again, this may result 
from mutation-dependent changes in protein stability, and therefore represents protein 
homeostasis found in ALS patients. Lastly, we wanted to further characterize the 
interaction and wondered whether it was RNA-dependent, as FUS interacts with 
proteins in both RNA-dependent and RNA-independent manners. Upon treatment of the 
lysate with RNase A, we determined that mutant-FUS and hnRNP U still interact (Fig. 
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2.1D). These data suggest that hnRNP U interacts specifically with mutant FUS in an 
RNA-independent manner. 
 
Reduction of FUS interactor hnRNP U ubiquitously is pathological 
 How might the interaction between hnRNP U and FUS lead to MN degeneration? 
In order to answer this question, we first wondered whether hnRNP U has a normal role 
in cells and specifically MNs. Previous work shows that hnRNP U reduction in vivo 
constitutively and specifically from the heart is lethal (Roshon & Ruley 2005; Ye et al. 
2015) and elimination in vitro from neurons causes cell death (Suzuki et al. 2015); 
however its role in vivo in MNs has not yet been described. 
 Using a conditional hnRNP U knockout mouse (Fig. 2.2A) (Ye et al. 2015), we 
first generated a knockout allele and observed mice hemizygous for hnRNP U. As 
detected by western blot, reduction of hnRNP U in hemizygotes was mild and not 
statistically significant (Fig. 2.2B); however the mild reduction had detrimental effects. In 
crossing WTs to hemizygotes, Mendelian ratios predict 50% of offspring will be WT and 
50% will be hemizygotes. In actuality, 63% were WT and 37% hemizygotes (N = 110 
animals), suggesting that the hnRNP U knockout allele is maladaptive and selected 
against embryonically. Additionally, the hemizygotes that were born were smaller than 
their WT littermates (Fig. 2.2C) and this size differences persisted into adulthood, 
indicating that hnRNP U reduction is pathological (Fig. 2.2D). 
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Loss of hnRNP U in motor neurons results in premature death, denervation, and 
motor neuron abnormalities 
To determine the role of hnRNP U in motor neurons specifically, we crossed a 
ChAT-Cre deleter line to the hnRNP U conditional knockout mouse. In comparison to a 
hemizygous control, hnRNP U was efficiently eliminated from 100% of MNs (Fig. 2.3A). 
In addition to being smaller than hemizygous littermate controls (Fig. 2.3B), MN 
knockouts had a reduced lifespan (Fig. 2.3C). At P30, MN knockout mice reached 
“endstage” and were no longer able to right themselves when places on their side or 
back and were therefore euthanized. 
 We next asked whether MN pathology, such as MN loss and denervation, was 
evident following hnRNP U elimination and contributed to the shortened lifespan. We 
counted ChAT positive MNs in the ventral horn of L5 spinal cord at endstage, and we 
observed no statistically significant difference in L5 MNs (Fig. 2.4A). However upon 
analysis of the muscle, we observed denervation of three ALS-susceptible muscles in 
MN knockouts: the diaphragm, tongue, and tibialis anterior (TA) (Fig. 2.4B). Lastly, 
visualization of lumbar MNs with MN marker ChAT and nuclear envelope marker nup50 
revealed that hnRNP U elimination caused morphological abnormalities in >30% MNs 
(Fig. 2.4C). Nuclei did not appear spherical and instead were misshapen and eccentric. 
Together, these data suggest that hnRNP U has an essential role in MNs and its 
elimination causes morphological and functional abnormalities that lead to death.  
HnRNP U is not a component of FUS aggregates in ALS patients 
 As a key hallmark of ALS in patients is protein aggregation, we asked whether 
hnRNP U was a component of FUS aggregates. Using spinal cord tissue from a 
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FUSP525L/WT patient, immunocytochemical results suggest that hnRNP U is not present 
in FUS aggregates (Fig. 2.5), however further biochemical experiments are needed as 






















2.3 Discussion and future experiments 
 
Mutant FUS interacting proteins 
 The generation of a faithful ALS mouse model in our lab permitted further 
analysis of gain of toxic function mechanisms associated with FUS mutations. We 
reasoned that mutations result in compartmental and conformational differences 
between wild type and mutant FUS that cause mutant FUS to interact with different 
proteins than the wild type. As a protein’s role is in large part determined by the other 
proteins with which it interacts, we hypothesized that changes in protein-protein 
interactions were a proximal event in mutation-associated toxicity, and therefore to 
understand toxic gain of function mechanisms we first need to understand differences in 
protein-protein interactions. We used an unbiased mass spectrometry approach to 
identify 22 proteins that interact with P525L-mutant FUS, and subsequent validation 
indicated that these are aberrant interactions, likely due to mutation-dependent changes 
in protein conformation and stability. 
 Most of the mutant-FUS interactors are RNA binding proteins with roles in RNA 
splicing, processing, and stabilization. Many of the proteins are ribosomal proteins, 
consistent with FUS localization to polysomes and its role in local protein synthesis 
(Belly et al. 2005), and many are involved in various steps of RNA processing including 
mRNA granule transport, splicing, miRNA maturation, and translation. In addition, many 
interactors are components of RNA granules, specifically stress granules. 
 Comparisons with other data sets reveal similarities and differences in protein 
interactions and common cellular pathways. The first paper to publish a wild type FUS 
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interactome used a HeLa overexpression system and revealed that most FUS 
interactors are RNA binding proteins, many of which are involved in RNA splicing, and 
interact with FUS in an RNA-dependent manner (Yamazaki et al. 2012). Significantly, 
FUS interacted with spinal muscular atrophy protein survival motor neuron (SMN) and 
TDP-43, however subsequent work in our lab has failed to reproduce these interactions 
(Dr. Bea Blanco, personal communication), suggesting that it may be an artifact of the 
overexpression system. 5 interactions with wild type FUS were identified as mutant-FUS 
interactors in our system (Table 2.2). 
 Additional studies have identified interacting proteins with mutant and wild type 
FUS. In one HEK293 cell overexpression system, most FUS interactors were related to 
metabolism and protein degradation, as well as RNA metabolism (Wang et al. 2015). 6 
proteins were also found in our dataset including hnRNP U, and SFPQ showed an 
increased interaction with mutant FUS as we see in our system. Another system 
expressed mutant and wild type FUS in a neuronal cell line and identified FUS 
interactors that were largely DNA/RNA binding proteins with roles in RNA metabolism 
(Blokhuis et al. 2016). 9 proteins overlapped with those in our system including hnRNP 
U, and 8 of these proteins were also interactors of TDP-43 and ALS-related protein 
Ataxin-2, suggesting these proteins may be involved in common ALS downstream 
mechanisms. Interestingly, no interaction between FUS and SMN was identified, 
despite the authors reporting an interaction in a previous publication (Groen et al. 2013). 
Lastly, a group used FUS overexpression in HEK293T cells to identify RNA-dependent 
and RNA-independent interactors with mutant and wild type FUS, identifying many of 
both that were almost exclusively related to RNA metabolism (Kamelgarn et al. 2016). 8 
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proteins overlapped with those in our system including hnRNP U, and interestingly the 
interaction with hnRNP U was independent of RNA, consistent with the results reported 
in this thesis.  
These data therefore are largely consistent with other reports of FUS interacting 
proteins. 8 mutant-FUS interacting proteins (hnRNP U, hnRNP R, hnRNP K, Fxr1, 
G3bp2, SFPQ, Ddx1, and Caprin1) were common to at least 3 datasets including that 
presented in this thesis, suggesting they are bona fide interactors. 9 identified proteins 
are novel interactors, and future work will be required to determine the function of these 
interactions. 
In comparison to other work described above, this mass spectrometry 
experiment identified a small number of FUS-interacting proteins (22 vs. 112, 157, 166, 
or 124). This is likely due to the low expression levels of hFUS from the MAPT locus in 
comparison to endogenous FUS levels (Sharma et al. 2016). In addition, hFUS is only 
expressed in Tau-expressing cells, and together these suggest the myc-tagged protein 
is not abundant in the cell lysate and we therefore identified only the most abundant 
FUS interactions. While the number of interactors is low, the fidelity seems high, as 8 
out of 8 tested interactions from the top and bottom of the list were successfully 
validated. 
Particularly interesting is the correlation between the amount of the interactor co-
immunoprecipitated and the clinical severity of the mutation. For example, hnRNP U 
was more abundant in the precipitate of the clinically severe juvenile onset P525L-
mutant as compared to the clinically typical adult onset R521C-mutant, and no hnRNP 
U was present in the WT precipitate. While these differences may simply result from 
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differences in protein stability and therefore protein levels (Sharma et al. 2016), the 
differences are ultimately mutation-dependent, whether the result of altered binding 
affinity or protein levels, and therefore may be mechanistically relevant.  
 
Possible disease mechanisms 
 The aberrant interactions between mutant FUS and the RNA binding proteins 
described above suggest a few possible disease mechanisms that may lead to motor 
neuron loss. 
 Many of the interacting proteins including Caprin 1, Fxr1, and Ddx1, and in 
particular those common to multiple data sets, are components of stress granules. 
Stress granules are membrane-less subcellular structures that form in response to cell 
stress and serve to ensure that a cell is focusing resources on that which is needed to 
survive and combat the stress. In addition, FUS and TDP-43 aggregate with other 
stress granule proteins in ALS patients, suggesting their role in disease. Mutant FUS 
and other stress granule proteins may therefore promote degeneration in a few ways. 
These aberrant interactions in stress granules may promote abnormal protein 
fibrillization, which may eventually lead to aggregation. Protein fibrils or aggregates may 
be toxic through unidentified gain of function mechanisms and/or in addition may 
sequester RNA and proteins, inducing toxicity through the loss of function of specific 
RNAs and proteins.  
 Relatedly, many of the protein interactors harbor a low complexity domain, 
including hnRNP U, SFPQ, and Caprin 1. The low complexity domain is important in the 
manifestation of toxicity associated with FUS and other ALS mutations, possibly through 
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altered phase separation of RNA granules. The aberrant interaction between mutant 
FUS and other proteins with low complexity domains may therefore lead to 
degeneration through altered phase separation of FUS and its interacting proteins. 
While still unclear the specific toxic consequence of altered phase separation, 
possibilities include similar protein aggregation and sequestration of RNA binding 
proteins and mRNAs as was described above. 
 One way to test these hypotheses is to determine the context of the aberrant 
protein-protein interactions. Are these interactions occurring within cellular complexes 
such as stress granules? Are these interactions changing the solubility (and therefore 
propensity to aggregate) of the FUS complexes? Biochemical experiments, such as 
sucrose gradients and solubility fractionation will be able to probe whether these 
interactions are occurring within particular complexes in specific cellular compartments 
in order to ultimately determine disease mechanisms. 
 An attractive hypothesis from these models is that mutant FUS sequesters 
specific RNA binding proteins through these aberrant interactions, and it is the loss of 
function of specific RNA binding protein(s) that is ultimately toxic. Support for this 
sequestration hypothesis comes from mechanistically understood diseases such as 
Myotonic Dystrophy in which nuclear RNA foci sequester muscleblind and it is the loss 
of function of these proteins that is pathogenic. The sequestration hypothesis has also 
become popular in ALS due to observation of RNA foci associated with the 
hexanucleotide repeat expansion in C9orf72, the most common genetic cause of ALS. 
These foci are hypothesized to sequester RNA binding proteins, and an attractive 
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hypothesis is that the same proteins are sequestered by mutant FUS and by RNA foci, 
providing a common downstream disease mechanism. 
To further explore disease mechanisms, we took a candidate approach to 
determine whether a specific interactions was disease relevant. Due to its previous 
connection to ALS research and abundance as a mutant-FUS interactor, we pursued 
the relevance of hnRNP U to ALS. We showed that it was reciprocally pulled down with 
myc (pulling down human FUS) and hnRNP U antibodies, and then we showed that the 
interaction was independent of RNA. As previous reports have shown, many FUS 
interactions are RNA-dependent, and some are RNA-independent (Kamelgarn et al. 
2016). The RNA independence could suggest that FUS and hnRNP U bind directly to 
each other as opposed to associating in the same ribonucleoprotein complex, and 
binding assays could determine whether this is the case. 
 Future work will determine the relevance of interactors in humans and further 
characterize the nature of these interactions. We will seek to validate these mutation-
dependent interactions in humans using ALS-patient-derived spinal cord samples and 
induced pluripotent stem cells. We did not find hnRNP U to be a component of FUS 
aggregates, and as FUS-dependent motor neuron disease does not depend on protein 
aggregation, this observation does not preclude mechanistically-relevant protein 
mislocalization. Cytoplasmic mislocalization may cause a loss of protein function, and 
while FUS loss of function is insufficient to cause ALS, the loss of other RNA binding 
proteins may indeed be sufficient. Therefore we will determine whether the aberrant 
hnRNP U-FUS interaction occurs in the cytoplasm or the nucleus through subcellular 
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fractionation experiments. Mislocalization of RNA binding proteins may also alter RNA 
granule dynamics, leading to motor neuron death by a still undetermined mechanism. 
 
HnRNP U is essential ubiquitously and in motor neurons 
In addition to uncovering a potential role for hnRNP U in ALS, we also 
investigated its role generally and in motor neurons. Using genetic experiments, we 
show that hnRNP U reduction is toxic as hnRNP U hemizygotes, despite non-
statistically-significant reduction in hnRNP U levels, are not born at Mendelian ratios 
and are smaller than controls, suggesting that the knockout allele is maladaptive. 
Additionally, we present the first evidence in vivo that hnRNP U elimination in motor 
neurons is toxic. HnRNP U motor neuron knockouts die around P30, have denervation 
of the tongue, diaphragm, and tibialis anterior muscles, and have abnormal nuclear 
morphology in motor neurons. Further work will characterize whether hnRNP U 
elimination in motor neurons results in the same cell type vulnerabilities as in ALS. As 
the diaphragm, tongue, and tibialis anterior are all vulnerable in ALS, analysis of ALS-
spared motor neurons such as the oculomotor neurons or the less vulnerable soleus will 
determine whether hnRNP U elimination is generally toxic, or whether it is selectively 
toxic in a way that suggests ALS relevance. 
Still unknown is the mechanism by which hnRNP U reduction is toxic, however 
several essential functions for hnRNP U have previously been described. HnRNP U is a 
critical cellular protein, like many other hnRNPs. Its expression 2 to 5 times lower than 
wild type led to morphological abnormalities and death by embryonic day 11.5 (Roshon 
& Ruley 2005). Selective elimination from the heart resulted in abrupt death around 
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postnatal day 14 due to heart failure, with features comparable to those in humans with 
a heart condition due to a non-hnRNP U genetic mutation (Ye et al. 2015). In vitro, its 
reduction from motor neuron cell line NSC34 led to caspase cleavage, indicating cell 
death (Suzuki et al. 2015). Together, these data indicate hnRNP U is an essential 
protein that may be required ubiquitously or in specific cell types and not just in motor 
neurons. Future experiments using conditional knockout animals and different cre lines 
will determine whether motor neurons are preferentially vulnerable, which may explain 
cell type specificity in ALS, or whether there is a general requirement for hnRNP U. 
Many specific roles for hnRNP U have been described. HnRNP U was initially 
identified as an abundant RNA and DNA binding protein and a component of the 
nuclear matrix, suggesting its roles in maintaining nuclear architecture and regulating 
transcription (Romig et al. 1992; Dreyfuss et al. 1984). HnRNP U is also cleaved by 
caspase 3 during apoptosis resulting in a loss of DNA binding and detachment from the 
nuclear matrix, suggesting hnRNP U may be involved in the nuclear breakdown during 
apoptosis (Göhring et al. 1997; Kipp et al. 2000). It is recruited to sites of DNA damage 
and plays an important role in base repair (Hegde et al. 2012; Berglund & Clarke 2009; 
Britton et al. 2009; Britton et al. 2014), and in addition binds to intronic DNA to regulate 
aspects of development (Zhao et al. 2009). Thus through interactions with DNA and 
other proteins, hnRNP U has diverse functions in regulating gene expression and 
nuclear organization. 
It has similarly diverse roles in regulating gene expression at the RNA level 
through protein-protein and protein-RNA interactions. Firstly, it regulates RNA 
polymerase II-mediated transcription through interactions with transcription factors, 
61 
 
actin, and RNA polymerase II itself (Kukalev et al. 2005; Kim & Nikodem 1999). It also 
binds to RNA through its RGG domain, and through interactions with noncoding RNAs 
and other splicing factors it regulates mRNA stability and alternative splicing (Kiledjian & 
Dreyfuss 1992; Xiao et al. 2012; Hacisuleyman et al. 2014; Liu & Dreyfuss 1996; 
Yugami et al. 2007). Indeed, its elimination in the heart results in widespread defects in 
alternative splicing (Ye et al. 2015). 
HnRNP U is primarily nuclear, but biochemical and immunocytochemical 
experiments suggest it also localizes to the cytoplasm (Howell et al. 2004). It 
translocates to the cytoplasm upon stimulation of toll-like receptors, implicating it in the 
proinflammatory cellular response (Zhao et al. 2012), however cytoplasmic expression 
and functions in other cell types have not yet been described. 
 While work has been done to describe hnRNP U’s normal role in the cell, there is 
less known about its potential role in disease. It is a candidate for a deleted gene 
causing intellectual disability, developmental delay, and seizures (Caliebe et al. 2010; 
Thierry et al. 2012), and it has previously been connected to ALS through interactions 
with ubiquilin-2 and TDP-43 (Gilpin et al. 2015; Suzuki et al. 2015). Together, these 
data suggest that hnRNP U plays a role in ALS and other neurological deficits, however 
further work will be required to better define the potential disease mechanisms. 
As described above, hnRNP U has diverse functions in regulating gene 
expression and nuclear architecture, and hnRNP U elimination is likely toxic due to 
functional effects on one or more of these processes. As motor neuron elimination 
results in nuclear morphological abnormalities, we hypothesize that the toxicity in motor 
neurons relates in part to hnRNP U’s role in maintaining nuclear architecture. We 
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expect deeper understanding of hnRNP U function will enable better understanding of 
its role in disease. 
 
Role of hnRNP U-FUS interaction 
 Work presented in this thesis demonstrates FUS mutations cause an aberrant 
interaction between FUS and hnRNP U. Together with the data that hnRNP U 
elimination in motor neurons is toxic, we propose a sequestration model in which the 
mutant FUS - hnRNP U interaction prevents hnRNP U from executing its normal 
function, leading to toxicity by a loss of hnRNP U function (Fig. 2.6). This hypothesis 
leads to two predictions: decreasing hnRNP U levels would aggravate mutant FUS-
dependent toxicity and increasing hnRNP U levels would rescue mutant-FUS 
dependent toxicity. Future experiments will entail genetically testing these predictions by 
crossing an hnRNP U knockout allele into the FUS mouse model of ALS generated in 
the Shneider lab and by injecting virally encoded hnRNP U into the cerebrospinal fluid 
to increase protein levels in motor neurons.  
The observation that hnRNP U elimination causes an abnormal nuclear 
morphology suggests defects in the nuclear architecture may ultimately be the cause of 
neurodegeneration. One function of the nuclear matrix is to connect the nucleus to the 
cytoplasm both structurally and functionally, enabling nucleocytoplasmic transport and 
proper nuclear positioning. Two complexes- the nuclear pore complex and the LINC 
complex- serve these functions and are intimately connected to lamins and the nuclear 
membrane in which they reside.  
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Additional research supports role of hnRNP U in nucleocytoplasmic transport 
defects. The abnormal nuclear morphology associated with hnRNP U elimination in 
motor neurons also resembles that in laminopathies such as Hutchinson Gilford 
Progeria Syndrome in which a nuclear envelope residing lamin is mutated (Liu et al. 
2011; Zhang et al. 2011; Miller et al. 2013). Lamins maintain the structure of the nuclear 
envelope and associate with both the nuclear pore and LINC complexes such that the 
interaction between these complexes facilitates nucleocytoplasmic transport (Jahed et 
al. 2016). The specific function of hnRNP U in the nuclear matrix is unclear, however it 
is known to interact Lamin B, one of the primary components of the nuclear envelope 
(Lobov et al. 2001), and future work will determine whether FUS mutations perturb this 
interaction.  
Recent work also suggests defects in nucleocytoplasmic transport through the 
nuclear pore complex are a key pathological mechanism associated with the ALS-
causal repeat expansion in C9orf72. Two unbiased screens identified proteins involved 
in the nuclear pore complex as modifiers of C9orf72-mediated toxicity (Jovičić et al. 
2015; Freibaum et al. 2015). Additionally, the nuclear envelope was disrupted in cellular 
and animal models of ALS as well as ALS patients, and studies using iPS lines derived 
from ALS patients verified the nucleocytoplasmic transport defects (Zhang et al. 2015; 
Freibaum et al. 2015; Jovičić et al. 2015; Kinoshita et al. 2009).  
Taken together, these data suggest that hnRNP U sequestration by mutant FUS 
may have the downstream consequence of altering nucleocytoplasmic transport by 
perturbing the nuclear matrix in a manner similar to C9orf72 repeats, further implicating 




 The work presented in this Chapter suggests novel aberrant interactions between 
mutant FUS and other RNA binding proteins that may ultimately lead to understanding 
gain of function mechanisms associated with FUS mutations, and in addition that have 
enabled better understanding of the role of RNA binding protein hnRNP U in motor 
neurons. We suggest that aberrant FUS-RNA binding protein interactions may result in 
toxicity due to alterations in stress granule dynamics, RNA granule phase separation, 
and/or sequestration of RNA binding proteins, specifically hnRNP U. These areas of 
research remain active areas of study in the lab today, and future work will empirically 
test the potential disease mechanisms described above. Together, these data suggest 
the potential sensitivity of a cell (and perhaps specifically motor neurons) to changes in 
the concentration of RNA binding proteins and highlight the value in carefully generated 






Figure 2.1: Identification and chatacterization of hFUS interactors. 
A. Schematic of mass spectrometry (MS) experiment. Using myc antibody, human FUS 
was co-immunoprecipitated with interacting proteins from mouse spinal cord, and 
interactors were identified by MS. B. Silver stain of samples submitted for MS with size 
markers in kDa on the left. Bands in wild type (WT) lane represent background. 
Examples of differences between hFUS samples are indicated with asterisk (*). C. Co-
immunoprecipitation with myc antibody reveals validation of MS-identified interactions 
with P525L-mutant hFUS and altered interactions with R521C-mutant or WT- hFUS. WT 
lane represents non-myc-expressing, C57BL/6J mouse. mFUS- mouse FUS; hFUS- 
human FUS. D. Co-immunoprecipitation with hnRNP U antibody from hFUS-WT or 
hFUS-P525L expressing mice reveals interaction with mutant protein, and interaction 























     
            Days elapsed 
Figure 2.3: HnRNP U elimination from motor neurons results in premature death. 
A. Sections of lumbar spinal cord stained with MN marker ChAT and hnRNP U from 
control (hnRNP UKO) or MN knockout (Chat-Cre+/-; hnRNP UFL/KO) animals. Scale bar – 
25 µm. B. MN knockouts (red) are smaller than controls (black) at P24. (N = 5-8; 
***P<0.001 using t-test. Error bars represent s.e.m.). C. Shorter lifespan of MN 
knockouts compared to control. Kaplan-Meier plot showing the cumulative probability of 
survival of indicated genotypes. (N = 14-19 per genotype; log-rank test = 40.29; 
***P<0.001). 
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Figure 2.4: Loss of hnRNP U from motor neurons (MNs) causes denervation and 
MN abnormalities.      
A. Loss of hnRNP U in MNs does not cause L5 MN loss by endstage (P30). B. Loss of 
hnRNP U in MNs causes loss of innervation (denervation) of the diaphragm, tongue, and 
TA muscles at endstage. Example of diaphragm muscle stained with presynaptic marker 
synaptophysin (green) and postsynaptic marker tetramethylrhodamine-conjugated alpha-
bungarotoxin (Btox). Scale bar, 50 μm. C. Loss of hnRNP U in MNs causes abnormal 
nuclear morphology. Lumbar MNs stained with MN marker ChAT and nuclear envelope 
marker nup50. Scale bar, 25 μm. (For A and B, N = 4-6; ***P<0.001, **P<0.01, *P<0.1 
using t-test. Error bars represent s.e.m.). 





   
     
Figure 2.5: HnRNP U does not colocalize with FUS aggregates in FUS patients. 
Staining neurons with neuronal marker NeuN, FUS, and hnRNP U from an ALS patient 
with a P525L mutation in comparison to a control reveals that hnRNP U remains nuclear 








Figure 2.6: Model for hnRNP U-dependent toxicity. 
Under normal circumstances, hnRNP U executes its RNA-processing functions in the 
cell. When mutant FUS is present, however, FUS aberrantly interacts with hnRNP U, 
leading to hnRNP U sequestration, loss of function, and subsequent neurodegeneration. 
















Protein hFUS-P525L WT 
hnRNP U 44 0 
hnRNP R 15 0 
hnRNP Q 14 0 
FUS 10 0 
hnRNP K 8 0 
Fxr1 7 0 
Dsg1a 7 2 
Rtcb 6 0 
Rbmxl1 6 0 
Habp4 6 0 
G3bp2 4 0 
Rps2 4 0 
Rps4l 4 0 
Rpl23a 4 0 
SFPQ 3 0 
Fbl 3 0 
Cnp 2 0 
Ddx1 2 0 
Caprin1 2 0 
Ubap2l 2 0 
Serbp1 1 0 
Pde4d 1 0 
 
Table 2.1: Proteins identified by mass spectrometry as mutant-FUS interactors. 
22 proteins were identified as hFUS-P525L interactors, most of which were RNA 
binding proteins. Proteins are listed with the number of spectral counts identified (a 














Protein Yamazaki et al. Wang et al. Blokhuis et al. Kamelgarn et al. 
hnRNP U   X X X 
hnRNP R X   X X 
hnRNP Q X   X   
FUS X       
hnRNP K   X X X 
Fxr1     X X 
Dsg1a         
Rtcb       X 
Rbmxl1         
Habp4         
G3bp2 X   X X 
Rps2         
Rps4l         
Rpl23a         
SFPQ   X X   
Fbl         
Cnp         
Ddx1   X X X 
Caprin1 X   X X 
Ubap2l   X     
Serbp1   X     
Pde4d         
 
Table 2.2: Proteins identified as FUS interactors in other data sets. 
Comparison of hFUS-P525L interactors identified in this thesis (left column) with 4 other 













Chapter 3: The TDP-43 knock-in model 
 
3.1 Introduction 
 TDP-43 inclusions are found in almost all ALS patients, and TARDBP mutations 
have been identified as causal for the disease, suggesting TDP-43 plays a central 
mechanistic role. Understanding the age-dependent mechanisms that underlie the 
toxicity of wild-type (WT) TDP-43 in ALS and related TDP-43 proteinopathies, and the 
effects of ALS-associated TARDBP mutations on this process will have important 
implications for the development of novel therapies for these disorders. 
TDP-43 is a DNA/RNA binding protein that functions in many aspects of RNA 
metabolism including splicing, translation and transport (Ratti & Buratti 2016). The 
functional sequestration of TDP-43 in nuclear and cytoplasmic aggregates and the 
nuclear exclusion of TDP-43 in ALS and related disorders may result in a loss-of-
function that underlies TDP-43 toxicity. Alternatively, ALS-related mutations or the 
aberrant processing of wild-type TDP-43 may lead to toxicity through a novel gain of 
function mechanism, possibly related to protein aggregation. 
Differentiating between loss and gain of function mechanisms is made difficult by 
our incomplete understanding of the functional consequences of TARDBP mutations.  
Studies of the effects of ALS-related mutations on TDP-43 function have also been 
complicated by the use of overexpression systems in which TDP-43 - with or without 
ALS-associated mutations - is toxic in a dose dependent manner (McGoldrick et al. 
2013). These models fail to reproduce key features of ALS, raising concerns about their 
relevance to ALS, and suggest that a more faithful genetic model is needed to 
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understand the role of normal and mutant TDP-43 function in motor neuron 
development, function and survival in health and disease. 
Here we report the generation of two TDP-43 knock-in mouse lines in which we 
introduced the ALS-causing mutation M337V or G298S into the mouse TARDBP gene 
to express mutant TDP-43 from the endogenous mouse locus, recreating the ALS 
patient genotype. This knock-in approach to model TDP-43-ALS in the mouse 
overcomes the issues of overexpression that may complicate phenotypic analysis, and 
makes it possible to study the consequence(s) of disease-related mutation on TDP-43 





Generation of TDP-43 knock-in mice 
To determine the effects of TARDBP mutations on normal TDP-43 function and 
to model the toxicity of mutant TDP-43 faithfully, we recreated the human ALS genotype 
in the mouse by introducing ALS-associated mutations into the mouse TARDBP gene. 
Two causal mutations - M337V, one of the most common TDP-43 mutations, and 
G298S, associated with a shorter disease progression (Corcia et al. 2012), were each 
used to generate novel TDP-43 knock-in (TDP-43KIN) mouse lines (Fig. 3.1).  
 
Mutant TDP-43 is not associated with loss of function 
In the TDP-43 knock-in mice, an ALS allele replaces the endogenous (WT) gene, 
which makes it possible to address the effects of the mutation on protein function. TDP-
43 is critical for cell survival both during development and in adulthood, as 
demonstrated respectively by the lethality associated with TDP-43 elimination from the 
embryo or postnatally.  First, to determine whether the ALS-associated mutations 
M337V or G298S have any effect on the critical function(s) of TDP-43, we asked 
whether either of these alleles could overcome the lethality associated with the loss of 
TDP-43.  Using a TDP-43 knockout (TDP-43KO) allele (Sephton et al. 2009), we were 
able to generate both hemizygous (TDP-43KIN/KO) and homozygous (TDP-43KIN/KIN) 
animals with each of the M337V and G298S knock-in alleles in the expected Mendelian 
ratios. In all cases, the animals appeared normal at birth, indistinguishable from wild-
type and heterozygous (TDP-43KIN/WT) littermate controls. This early experiment 
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demonstrated that the M337V and G298S mutant alleles, causally related to ALS in 
patients, are both fully functional in the mouse in that they are able to rescue the 
lethality associated with TDP-43 loss-of-function, without any obvious functional 
consequences.    
 We next looked in the mutant mice to see whether these ALS-causing TARDBP 
mutations affect the level or pattern of TDP-43 expression in vivo.  Analysis of TDP-43 
protein and RNA levels of homozygous mice revealed that the mutations have no effect 
on RNA (Fig. 3.2A) or protein levels (Fig. 3.2B). TDP-43 is a predominantly nuclear 
protein, and its mislocalization to the cytoplasm in ALS has been implicated in the 
neurotoxicity of TDP-43.  To determine whether ALS-associated mutations in TARDBP 
directly cause cytoplasmic mislocalization of TDP-43, we analyzed TDP-43M337V and 
TDP-43G298S homozygous mice and observed that TDP-43 remains nuclear and does 
not mislocalize to the cytoplasm as a consequence of the mutations alone (Fig. 3.2C). 
One essential function of TDP-43 is in autoregulation of its own expression and precise 
maintenance of cellular TDP-43 levels. As even a modest excess of wild-type TDP-43 is 
toxic in a variety of systems (McGoldrick et al. 2013), any defect in the autoregulatory 
function of TDP-43 could lead to TDP-43 accumulation and toxicity. We used the hemi- 
and homo-zygous mutants to assess the consequences of the mutations on TDP-43’s 
ability to regulate its own expression. Although only one allele is active in the 
hemizygous (TDP-43KO/WT) mutants, TDP-43 protein levels are equivalent to that in wild-
type (TDP-43WT/WT) animals as a consequence of autoregulation (Fig 3.2D).  Similarly 
we observed equivalent amounts of TDP-43 in all knock-in mutant animals compared to 
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WT and hemizygous KO controls (Fig. 3.2D), demonstrating that the M337V and G298S 
mutations do not impair TDP-43 autoregulatory function. 
 
Heterozygous mutations are insufficient to cause motor neuron pathology 
 In ALS patients, TARDBP mutations typically cause late (adult) onset motor 
neuron disease, so we next asked about the age-dependent consequences of the 
M337V and G298S knock-in mutations on long term motor neuron health in 
heterozygous mice, which copy the human ALS genotype.  We looked for key 
pathological hallmarks of ALS, including motor neuron loss, muscle denervation and 
aggregation of TDP-43. Using an antibody against choline acetyl transferase (ChAT), 
we visualized and counted motor neurons in lumbar levels 4 and 5. At 1, 1.5 and 2 
years of age, we observed no difference in the average number of motor neurons in 
heterozygous TDP-43M337V and TDP-43G298S mice (TDP-43M337V/WT or TDP-43G298S/WT) in 
comparison to wild-type controls (Fig. 3.3B). 
 In ALS patients, fast-fatigable motor neurons are preferentially affected, and 
denervation of the neuromuscular junction (NMJ) in corresponding muscles precedes 
spinal motor neuron loss (Dengler et al. 1990; Fischer et al. 2004). We therefore 
examined the integrity of the neuromuscular junctions of the relatively vulnerable tibialis 
anterior (TA) muscle, which is predominantly innervated by fast-fatigable motor 
neurons, using an antibody against synaptophysin (syn) to label motor axon terminals, 
and a fluorescent conjugate of α-bungarotoxin (BTX) to label the post synaptic side of 
the neuromuscular junction.  At 1, 1.5, and 2 years of age, we found no increased 
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denervation of the TA endplate in heterozygous knock-in mice relative to wild-type 
controls (Fig. 3.3A). 
 Lastly, since TDP-43 inclusions are found in the large majority of ALS patients in 
both sporadic and familial cases, we looked for evidence of TDP-43 pathology in the 
spinal cord of TDP-43M337V and TDP-43G298S heterozygous mutants. Using antibodies 
against TDP-43 and ChAT, we found no evidence of abnormal TDP-43 aggregation in 
these knock-in mice at 2 years of age, and the localization remained nuclear (Fig. 3.3C). 
Together, these data demonstrate that in the TDP-43M337V and TDP-43G298S 
heterozygous knock-in mutants that faithfully model the human ALS genotype, we find 
no evidence of motor neuron degeneration.  
 
Homozygous mutations are insufficient to cause motor neuron pathology 
 The mechanisms by which dominant mutations in TARDBP cause ALS are not 
known, but many ALS-associated alleles are not fully penetrant in humans, and so it is 
perhaps not surprising that the equivalent mutations in the knock-in mice are alone 
insufficient to cause motor neuron degeneration. In this age-dependent disease, several 
factors – environmental and genetic - likely contribute to the onset and progression of 
disease. One determinant of disease onset may be levels of TDP-43 expression, as an 
excess of even wild-type TDP-43 is toxic. In this threshold model of disease, local 
increases in protein concentration on a cellular level may underlie toxicity, and mutant 
forms of TDP-43 may more easily reach the critical threshold required to elicit motor 
neuron pathology. Given that the mouse TDP-43M337V and TDP-43G298S alleles both 
appear to be fully functional, we asked whether higher levels of mutant TDP-43 in 
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homozygous knock-in animals could elicit a motor neuron phenotype. At 1, 1.5, and 2 
years of age, we observed no excess motor neuron degeneration (Fig. 3.4B), TA 
denervation (Fig. 3.4A) or mislocalization and aggregation (Fig. 3.4C) in the TDP-
43M337V or TDP-43G298S homozygous knock-in animals compared to wild-type controls. 
Although all of the TDP-43 in these homozygous animals was ALS mutant protein, twice 
the physiological level of mutant TDP-43 was insufficient to cause motor neuron 
degeneration. 
 
TDP-43 remains soluble in knock-in mutants 
 Although we found no evidence of motor neuron degeneration in the TDP-43 
knock-in mice, we looked for other abnormalities that may suggest early signs of TDP-
43 toxicity in motor neurons. At end-stage in ALS patients, TDP-43 becomes insoluble 
(Fig. 3.5A) and cytoplasmic inclusions form in degenerating neurons and surrounding 
glia (Neumann et al. 2006; Arai et al. 2006). These changes in TDP-43 localization and 
solubility likely precede motor neuron degeneration, so we looked in the knock-in mice 
for biochemical evidence of early TDP-43 pathology. 
 We carried out fractionation experiments to separate out the soluble, sarkosyl-
soluble, and sarkosyl-insoluble proteins from the brain of 2-year-old knock-in animals. 
Upon probing for TDP-43, we observe no differences in TDP-43 solubility in the knock-




Knock-in animals do not show gliosis 
 In other SOD1 and FUS models of ALS and in ALS patients, motor neuron 
degeneration is accompanied by an inflammatory response in the ventral horn of the 
spinal cord (Bruijn et al. 1997; Sharma et al. 2016; Schiffer et al. 1996). To look for 
evidence of astrocytosis and microgliosis in the TDP-43KIN mice, we stained the lumbar 
spinal cord of TDP-43M337V and TDP-43G298S hetero- and homo-zygous mutants with 
antibodies for glial fibrillary acidic protein (GFAP) and Iba1, specific for astrocytes and 
microglia respectively. At 2 years of age we observe no differences in GFAP or Iba1 
immunoreactivity in knock-in animals as compared to wild-type controls (Fig. 3.5C), 
demonstrating no evidence of cellular inflammation in this model. 
 
Mouse and human TDP-43 are similarly toxic 
While a great advantage of the knock-in system is expression of mutant TDP-43 
from the endogenous locus, the differences between mouse and human TDP-43 may 
make the mutant mouse protein less pathogenic and underlie the absence of pathology. 
The proteins are >96% identical with only 16 amino acid differences, however, most 
differences cluster in RRM2 and the low complexity domain, two regions which are 
important in TDP-43 aggregation (Fig. 3.6A). To address this caveat, I performed 
toxicity experiments in yeast as described previously to determine whether mouse and 
human TDP-43 were similarly toxic (Johnson et al. 2009). TDP-43 was expressed in 
yeast under the control of a galactose inducible promoter such that when yeast were 
grown in glucose there was no TDP-43 expression, however upon growth in galactose, 
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TDP-43 was robustly expressed. Using spotting assays, both mouse and human TDP-
43 caused similar toxicity upon growth in galactose (Fig. 3.6B). Additionally, the growth 
rates of the yeast upon expression of mouse or human TDP-43 were significantly slower 
than an empty vector control but not different from each other (Fig. 3.6C), suggesting 























 TDP-43 inclusions are a common pathological feature of nearly all patients with 
sporadic and familial forms of ALS.  This, together with the identification of causal 
mutations in TARDBP strongly support the idea that TDP-43 plays a key role in the 
pathogenesis of ALS and other TDP-43 proteinopathies (Geser et al. 2009), but the 
mechanism of TDP-43-dependent neurodegeneration remains elusive.  
More than 15 mouse models have been reported in which wild type and ALS 
mutant forms of human TDP-43 are exogenously expressed (McGoldrick et al. 2013; 
Arnold et al. 2013; Walker et al. 2015; Stribl et al. 2014). Though a neurodegenerative 
phenotype is observed in these animals, the disease relevance of these models to ALS 
is uncertain. Differences in the level and pattern of TDP-43 expression in these mice 
have led to considerable variability in motor phenotypes. In some mice, premature 
death is accompanied by motor neuron loss and denervation, and others it is not. In 
some but not others, a motor phenotype is accompanied by TDP-43 aggregation and 
misprocessing. Survival phenotypes range from less than 3 weeks to upwards of 1 year. 
Additionally, in some but not all systems, the overexpression of wild type TDP-43 leads 
to a similar motor phenotype as that observed with the overexpression of mutant TDP-
43, suggesting that overexpression of TDP-43 is itself toxic in a way that may not be 
disease relevant. The normal function of TDP-43 to regulate its own protein levels 
through a negative feedback loop underscores the importance of maintaining TDP-43 
levels within a precise physiological range. Therefore, any effort to model TDP-43 
83 
 
pathology by ectopic overexpression of this protein will override this autoregulation, 
possibly resulting in phenotypes unrelated to human motor neuron disease.  
Similarly, TDP-43 loss-of-function models may not reproduce the disease 
phenotype, and the lethality associated with widespread TDP-43 elimination in 
development (Wu et al. 2010) or postnatally (Chiang et al. 2010), or the cell 
autonomous effect of TDP-43 elimination in motor neurons (Iguchi et al. 2013; Wu et al. 
2012) may simply reflect the loss of a critical regulatory protein, whether or not that 
occurs in ALS in the course of disease. Despite the abundance of systems, the role of 
TDP-43 activity in motor neuron survival and the effect of ALS-causing TARDBP 
mutations on physiological or toxic functions of TDP-43 has not been determined.    
 To overcome the potential artifacts associated with overexpression of exogenous 
TDP-43 in vivo and produce an unbiased animal model, we generated a novel knock-in 
mouse expressing ALS-mutant TDP-43. In this model, we inserted ALS-associated 
mutations into the mouse TARDBP genetic locus so that heterozygous TDP-43KIN 
mutants express TDP-43 at a physiological level and in a pattern that mimics ALS 
patients with the equivalent mutations. The great advantage of this system is that it 
makes possible a genetic approach to assess the consequence of ALS-associated 
mutations on normal TDP-43 function when crossed to the knockout allele or in the 
homozygous mutants, and permits the study of increasing dosage of mutant TDP-43 on 
motor neuron survival.      
 Using this mouse, we first demonstrated that the TDP-43M337V and TDP-43G298S 
alleles are fully functional since in the hemizgyous mutants (TDP-43M337V/KO, for 
example), both rescue the embryonic and postnatal lethality of TDP-43 loss of function. 
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These ALS-causing TARDBP mutations also do not influence TDP-43 protein or RNA 
levels, change cellular localization of this nuclear protein, or interfere with the 
autoregulation of TDP-43 levels that underlie its critical role in cell survival. Importantly, 
homozygous mutant mice are indistinguishable from wild type mice, suggesting that the 
mutant protein retains normal activity.  
These data examine in vivo for the first time in the mouse the effects of TARDBP 
mutations on properties of the protein in the absence of wild type protein, which 
confounds data interpretation in previous studies. Interestingly, these data are 
inconsistent with observations in zebrafish, in which mutant TDP-43 expression could 
not rescue the motor defects associated with TDP-43 reduction (Kabashi et al. 2009). 
This discrepancy may indicate differing roles of mutations on TDP-43 function between 
vertebrates and invertebrates, and perhaps specifically in development, or may be a 
result of the overexpression approaches used to express TDP-43 in zebrafish. Due to 
the increased similarity of mice to humans and the cleaner genetic approach, the results 
from the knock-in mouse model system are likely more relevant to humans and disease.  
These data demonstrate that the mutations themselves do not affect TDP-43 
function, providing evidence against a primary loss of TDP-43 function in ALS. While 
loss of function does not seem to be a direct consequence of mutations themselves, it 
may be a secondary consequence of protein aggregation and TDP-43 sequestration, 
and therefore we cannot rule out loss of function as a downstream disease mechanism. 
This suggests TARDBP mutations cause a gain of function toxicity, perhaps through 




Both time (age) and mutations seem to have similar effects on TDP-43 
pathogenic behavior, and therefore understanding the long-term consequences of the 
mutations on motor neuron health will likely be relevant to ALS broadly. In older 
heterozygous and homozygous mice, we report an absence of motor neuron pathology, 
as determined by motor neuron loss, denervation, TDP-43 aggregation and insolubility, 
and gliosis. One explanation for the absence of pathology is the flaws with the mouse 
model system. As aging is an established risk factor for ALS, it is possible that a certain 
amount of time is required for pathology to accumulate to a pathological level, and the 
mouse lifespan (approximately 2-3 years) is simply not long enough. In support of this 
hypothesis, juvenile onset, aggressive ALS mutations result in a motor phenotype when 
mice are between 1 and 2 years old, and therefore adult onset mutations may not lead 
to pathology within the mouse lifespan (Scekic-Zahirovic et al. 2017). A second 
explanation is that differences between mouse and human TDP-43 mute the toxicity of 
mouse TDP-43. Expression studies in yeast modeled precisely after those previously 
reported (Johnson et al. 2009) indicate that mouse TDP-43 is as toxic as human TDP-
43, however future mutation analyses will be required to determine whether any of the 
mouse-human differences more subtly influence the biophysical properties of the 
protein. 
Alternatively, the mutations by themselves may be insufficient to precipitate 
motor neuron pathology, which is perhaps a likely explanation given the multitude of 
factors causing ALS in humans, and the additional factors causing disease in humans 
may be absent in this model system. Age, mutations, and sex are the biggest known 
risk factors, however the vast majority of ALS cases are still an etiological mystery. 
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These data suggest a stressor threshold hypothesis of motor neuron degeneration in 
ALS in which genetic mutations confer a predisposition in an individual to ALS but 
additional stressors, such as age, environmental toxins, and genetic modifiers, are 
required to reach the pathological threshold. The threshold hypothesis is also consistent 
with many observations from ALS patients. Most ALS cases onset in middle or old age 
suggesting age as a precipitating factor, however absence of ALS from the majority of 
the world’s population suggests it cannot be the only contributing factor. Additionally, 
ALS typically presents with focal onset, suggesting that external factors can change the 
local environment on a cellular level to induce selective degeneration, despite 
ubiquitous mutations. An advantage of this knock-in model is the ability to model the 
multifactorial nature and variability associated with ALS.  
 Future experiments will focus on the combination of external ALS relevant 
stressors with mutations to determine to which stressors mutations confer vulnerability. 
Strong candidates are genetic modifiers, which have previously been associated with 
the human disease. In addition, the genetic background of the mouse can greatly 
modulate ALS phenotypes in SOD1 mouse models, and unpublished work from our lab 
suggests this is true for human TDP-43 as well. A different TDP-43 animal model 
expressing human TDP-43 cDNA from the endogenous MAPT genetic locus yielded a 
paralysis phenotype by 18 months on a mixed C57BL/6 and Ola129 background, and 
this phenotype was completely abolished on a pure C57BL/6 background (Drs. Aarti 
Sharma and Helaina Lehrer, personal communication). Through crossing knock-in 
alleles onto other genetic backgrounds we will determine whether certain modifiers in 
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combination with TARDBP mutations are sufficient to reveal a phenotype, and further 
sequencing experiments could permit the identification of the modifying alleles. 
 Additionally, epidemiological data suggests environmental toxins as additional 
risk factors in ALS (McGeer et al. 1997; Oskarsson et al. 2015). Therefore, through a 
collaboration with Dr. Diane Re in the Environmental Health and Sciences department, 
we are asking whether TARDBP mutations can combine with environmental factors to 
reveal a susceptibility of motor neurons. From preliminary experiments, knock-in motor 
neurons in vitro either from primary culture or differentiated from embryonic stem cells 
seem more susceptible to heavy metal toxicity than wild type, and whether this is true in 
vivo in the mouse and relevant to ALS remains to be determined (Dr. Diane Re, 
personal communication). 
 The presence of TDP-43 inclusions in ALS and the ubiquitous presence of 
protein aggregates in neurodegenerative disease in general suggests aggregation may 
be a common downstream mediator of disease through a prion-like mechanism by 
which TDP-43 adopts an abnormal protein conformation, templating further TDP-43 
aggregation and spreading from cell to cell. This prion-like mechanism would also 
explain the focality of ALS and regional spread, as TDP-43 aggregates would induce 
aggregation in neighboring cells and contiguously spread. Indeed in vitro experiments 
have documented the seeding ability of aggregated TDP-43. Insoluble patient-derived 
TDP-43 can trigger intracellular TDP-43 aggregation and insolubility in vitro, which can 
be propagated (Smethurst et al. 2016; Shimonaka et al. 2016; Furukawa et al. 2011; 
Nonaka et al. 2013). Still missing are in vivo experiments like those done with α-
synuclein in Parkinson’s disease (Luk, V. Kehm, et al. 2012; Luk, V. M. Kehm, et al. 
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2012) or Tau in Alzheimer’s disease (de Calignon et al. 2012), in which inoculation with 
aggregated TDP-43 in one brain or spinal cord region induces wild type or mutant 
protein to convert into a prion-like form and results in spreading neurodegeneration. I 
would predict that inoculation into even wild type animals would result in a propagating 
neurodegenerative phenotype, but that endogenous knock-in mutant TDP-43 would 
accelerate disease spread. 
 On a molecular level, a threshold that precipitates pathology may be reached 
from local increases in TDP-43 concentration resulting from alterations in the dynamics 
of RNA granules. Protein-protein interactions within these granules are mediated by 
interactions between the low complexity domains, and interestingly most ALS-causal 
TARDBP mutations fall within that domain and may increase aggregation propensity, 
suggesting they may influence TDP-43 interactions within RNA granules. Through 
phase separation experiments, it has been shown that ALS mutations in FUS and 
hnRNP A1, and C9orf72 change the dynamics of RNA granules and may promote time-
dependent protein fibrillization within RNA granules in a concentration dependent 
manner. The downstream consequences of this altered phase-homeostasis may include 
protein aggregation and the sequestration of RNA binding proteins, and we hypothesize 
this to be true with regards to TDP-43 as well. Exciting work recently demonstrated the 
formation of TDP-43-containing liquid-like granules in neurons in vitro, whose structure 
was dependent on localization within the axon, density, and aging (Gopal et al. 2017). 
M337V and G298S TARDBP mutations increased the viscosity of these granules and 
altered transport dynamics, providing an in vivo correlate of altered liquid-liquid phase 
separation and suggesting that decreased molecular mobility within RNA granules may 
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contribute to disease pathogenesis. Together, these data demonstrate the exquisite 
sensitivity cells in general, and perhaps motor neurons in particular, to their internal 
concentration of RNA binding proteins, and we suggest ALS-stressors act through 
altering these local concentrations to precipitate pathology. This knock-in model 
provides an ideal in vivo system in which to explore ALS-relevant factors that combine 
with age and mutations to alter the dynamics of RNA binding proteins and lead to TDP-






     
Figure 3.1: Generation of TDP-43 knock-in mice. 
A. M337V or G298S knock-in point mutations were inserted into the endogenous mouse 
TARDBP genetic locus with a neomycin cassette flanked by Frt sites for selection, 
which was removed by crossing to flippase mice. B. Southern blot analysis of targeted 
embryonic stem cell clones following BamHI digestion and hybridization with an external 
probe. Presence of Neo cassette yielded larger product (13.3 kb) than the wild type 
(11.6 kb). C. Sequencing of knock-in cells reveals a double peak, indicating the 
heterozygous presence of the point mutations. 
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Figure 3.2: Knock-in mutations do not affect normal TDP-43 properties. 
 A. Quantitative RT-PCR of TDP-43 from spinal cord extracts of knock-in homozygous 
mice in comparison to GAPDH. B. Western blot analysis of TDP-43 levels from spinal 
cord extracts of knock-in homozygous mice, quantified relative to GAPDH loading 
control. C. Confocal images of L5 spinal cord cross-sections of wild type (left) or 
homozygous M337V (center) and G298S (right) animals immunostained with anti-TDP-
43 and anti-ChAT antibodies. Scale bar, 25 μm. D. Western blot analysis of TDP-43 
levels from spinal cord extracts of homozygous or hemizygous (knockout = KO) wild 
type and mutant TDP-43 animals, with protein titration to semi-quantify signal 
difference. Protein levels quantified on the right relative to GAPDH. (For A, B, and D, N 










































Figure 3.3: Heterozygous knock-in mutants do not display ALS pathology. 
A. Representative images of tibialis anterior (TA) muscle immunostained with anti-
synaptophysin (syn) antibody and tetramethylrhodamine-conjugated alpha-bungarotoxin 
(Btox), and percent innervation quantified over 2 years. Scale bar, 100 μm. B. 
Representative images of L4-5 spinal cord immunostained with anti-ChAT antibody, and 
average MN number quantified over 2 years. Scale bar, 100 μm. C. Representative 
images of wild type (left) or heterozygous M337V (center) and G298S (right) L4-5 spinal 
cord immunostained with anti-TDP-43 and anti-ChAT antibodies from 2 year old mice. 







Figure 3.4: Homozygous knock-in mutants do not display ALS pathology. 
A. Quantification of TA muscle innervation over 2 year period. B. Quantification of 
average MN number per L4-5 spinal cord section over 2 year period. C. Representative 
images of wild type (left) or homozygous M337V (center) and G298S (right) L4-5 spinal 
cord immunostained with anti-TDP-43 and anti-ChAT antibodies from 2 year old mice. 





























Figure 3.5: Other ALS indicators absent from knock-in mice. 
Western blot analysis of TDP-43 levels in soluble, sarkosyl soluble, and insoluble 
protein fractions from an ALS patient with TDP-43 pathology and an age matched 
control (A) and 2 year old heterozygous and homozygous knock-in brain (B, N = 3). C. 
Glial reactivity (microglial marker Iba1 in green, DAPI in red, and MN outlined in white) 
within 100 μm of lumbar MNs from 2 year old heterozygous and homozygous knock-in 
animals. Microglia quantified in the center and astrocytes quantified on the right. (N = 3 
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Figure 3.6: Mouse and human TDP-43 both cause toxicity in yeast. 
A. There are 16 amino acid differences between mouse and human TDP-43 (indicated 
by gray bars), and most localize to RRM2 and the low complexity domain, regions that 
have been implicated in protein aggregation. B. Spotting assays upon expression of 
TDP-43 or an empty vector in yeast reveal both mouse and human TDP-43 cause 
toxicity. C. Growth rate did not differ between yeast expressing mouse or human TDP-
43. (For B and C, N = 3; for C, ***P<0.001 using one way ANOVA and error bars 
represent s.e.m.).  
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Chapter 4: Conclusions 
 
One of the fundamental questions in ALS is how a diverse set of genetic and 
environmental factors leads to a stereotyped, adult onset, neurodegenerative disorder 
primarily involving motor neurons. The genetics alone implicate a range of cellular 
processes that may be mechanistically involved, raising the question of whether various 
insults converge on common disease pathways or whether they initiate independent 
neurodegenerative mechanisms. Addressing this question requires systematic analysis 
of the consequences of ALS mutations to identify common or disparate disease 
processes, and this often occurs in animal model systems. 
Through the generation of animal models of ALS, we in the ALS field have 
learned valuable lessons about effective genetic approaches, with FUS mouse models 
best exemplifying these lessons. Early FUS rodent models of ALS involved 
overexpression by transgenic approaches, leading to toxicity due to protein 
overexpression that was not mutation-specific and associated with variable motor 
phenotypes (Huang et al. 2011; Verbeeck et al. 2012; Mitchell et al. 2013; 
Shelkovnikova et al. 2013). In contrast, more precise knock-in genetic approaches 
yielded two independent FUS models displaying a progressive and consistent ALS 
phenotype and leading to the same conclusion that FUS mutations are associated with 
a toxic gain of function (Sharma et al. 2016; Scekic-Zahirovic et al. 2017; Scekic-
Zahirovic et al. 2016). The controlled and physiological expression in these latter 
systems enabled unambiguous analysis of the consequences of FUS mutations, leading 
97 
 
to identification of relevant disease pathology and strong conclusions about disease 
mechanisms. 
While animal models of ALS have led to significant discoveries about disease 
mechanisms, many aspects of the disease have yet to be modeled in a mouse. In 
humans, ALS onsets in either bulbar, upper limb, or lower limb regions. In contrast, in 
mice, ALS has always onset in the lower limbs. In humans, there is regional spread of 
pathology to neighboring muscle groups, however no such observation has been 
recorded in mice. These data reveal potential mouse-human differences or a failure to 
model the complexity of ALS disease onset and progression. In addition, some 
mutations, such as ones in TARDBP, are incompletely penetrant in humans, however 
the same is not true in the mouse. Lastly, genetic-environment interactions contribute to 
disease in ALS, however these interactions have also yet to be modeled in the mouse. 
Future modeling efforts will be required to understand these important features of ALS 
pathogenesis. 
Through work presented in this thesis, we identified the aberrant protein-protein 
interactions that result from FUS mutations and may contribute towards FUS gain of 
function toxicity ALS. These interactions between FUS and other RNA binding proteins 
may lead to motor neuron loss by sequestering specific RNA binding p roteins, in 
general altering RNA metabolism, and/or leading to the formation of toxic and abnormal 
protein assemblies. From a therapeutic perspective, given that FUS is not required for 
long term motor neuron survival (Sharma et al. 2016), perhaps the most effective way to 
treat FUS-ALS would be to eliminate FUS. Antisense oligonucleotides are currently in 
use to alter or reduce expression of mutant proteins and may be a possible therapeutic 
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avenue in this case. Alternatively, or in addition, other RNA binding proteins whose 
function may be altered as a result of FUS mutations, such as hnRNP U, could be 
modulated in similar ways, and systematic analysis of these other FUS-interacting-
proteins will determine whether modulation is in fact therapeutic. 
In contrast to FUS, the more than ten different transgenic rodent models of TDP-
43 are hindered by the toxicity associated with overexpression of exogenous protein, 
which obscures analysis of the consequences of TARDBP mutations and therefore 
limits the utility of these systems for the study of ALS. Here we present the generation 
of the first rodent model system in which mutant TDP-43 is expressed at physiological 
levels under the control of endogenous regulatory elements. Interestingly, we found that 
the mutant protein is fully functional but alone is insufficient to cause motor neuron 
degeneration in ALS. Considering that even the aggressive FUS mutations associated 
with juvenile-onset ALS are associated with a late onset phenotype in the mouse, the 
absence of motor neuron pathology in the TDP-43 knock-in mice is perhaps not 
surprising. Nevertheless, the system makes it possible to study perturbations that reveal 
the increased vulnerability associated with TARDBP mutations. That the mutant protein 
is fully functional suggests TARDBP mutations are associated not with a primary loss of 
function but a gain of toxic function, which may ultimately lead to a secondary loss of 
function and/or other pathogenic consequences. In addition, the insufficiency of mutant 
alleles to cause motor neuron pathology further suggests the importance of maintaining 
TDP-43 levels within a physiological range: 2-fold overexpression is highly toxic, 
however “normal” mutant expression levels are not by themselves pathogenic. 
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The TDP-43 knock-in model suggests a threshold model of ALS in which many 
factors contribute to disease onset. This is supported by the observation that some 
ALS-related TARDBP mutations are not fully penetrant in families, and differences in 
background strain can influence the motor phenotype associated with a particular 
mutant TDP-43 transgene (Drs. Aarti Sharma and Helaina Lehrer, personal 
communication). We conclude from these observations that – to a greater or lesser 
degree – “causal” ALS mutations increase the likelihood of initiating the pathogenic 
mechanisms that lead to motor neuron degeneration in ALS. By themselves, specific 
mutations may be insufficient to cause disease and require additional stressors – 
innate/genetic and/or acquired/environmental. The FUS alleles used here meet the 
threshold to initiate pathology, but the TDP-43 knock-in alleles do not, indicating 
differences in pathogenicity associated with the mutations. We expect this model to be a 
useful tool for the ALS field to identify genetic modifiers and environmental stressors 
that combine to reach the critical threshold. 
How might combinations of stressors lead to TDP-43-dependent motor neuron 
disease? The presence of aggregates in ALS patients suggests they may be 
mechanistically relevant and facilitate disease propagation. If this is the case, the 
dissolution of protein aggregates may improve motor neuron survival, and protein 
disaggregases and remodeling enzymes have proven effective in suppressing 
aggregate-dependent toxicity (Jackrel et al. 2014). Indeed, this hypothesis is attractive 
for many reasons. First, it can explain the regional spread of ALS as local protein 
assemblies would propagate first to neighboring cells, then radially outward. Second, 
this mechanism implicates other functional categories of ALS-causal genes. Many ALS-
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related genes encode proteins involved in protein homeostasis including optineurin and 
valosin-containing protein. Loss of cellular functions in protein degradation and 
autophagy, for example, may lead to a similar accumulation of abnormal protein 
assemblies, thus initiating the propagating aggregation. Third, this mechanism is 
consistent with the threshold hypothesis of degeneration, as environmental factors and 
aging may impair the clearance of abnormal protein assemblies and bring the protein 
load over the necessary threshold to lead to toxicity. In addition, while a mutation may 
be one factor that brings a motor neuron closer to the threshold, age related changes 
with environmental factors may be sufficient to induce ALS in the sporadic cases. 
Testing this proposed mechanism will require seeding experiments like those done in 
Alzheimer’s (de Calignon et al. 2012) and Parkinson’s disease (Luk, V. M. Kehm, et al. 
2012; Luk, V. Kehm, et al. 2012) in which aggregated proteins, such as TDP-43 or FUS 
purified from ALS patients, are injected into a mouse to determine whether the 
aggregates can propagate and cause motor neuron pathology. 
While the mechanism described above explains many clinical, pathological, and 
genetic observations in ALS, protein aggregation is not a necessary component of some 
animal models of ALS, questioning its mechanistic importance. In the ALS-relevant 
mouse models of FUS-ALS and in some TDP-43 models of ALS, motor neuron 
degeneration is observed despite the absence of protein aggregation. Therefore while 
protein aggregation may be sufficient to propagate motor neuron pathology, it does not 
seem a necessary stressor in early stages of the disease process to reach the critical 
toxic threshold.  
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Alternatively, or in addition, the toxicity of TDP-43 may relate to aberrant protein-
protein interactions in a similar manner to mutant FUS. An attractive hypothesis is that 
similar RNA binding proteins, such as hnRNP U, are perturbed by both FUS and 
TARDBP mutations and abnormal TDP-43 assemblies. These aberrant interactions may 
be sufficient to sequester RNA binding proteins and thus lead to degeneration through 
an aggregation-independent mechanism, in which protein aggregation is an 
accelerating factor, an innocent bystander, or a protective event late in the disease. If 
this is the case, it will be necessary to determine whether it is the sequestration of 
specific RNA binding proteins or alteration of RNA binding protein concentrations as a 
whole that contributes to motor neuron pathology. In contrast to FUS, TDP-43 is 
required for postnatal motor neuron survival and overexpression leads to toxicity. 
Therefore altering TDP-43 expression is likely not a viable therapeutic strategy.  In this 
case, modulating the levels of specific RNA binding proteins using antisense 
oligonucleotide therapy may correct RNA metabolism defects and improve survival 
outcomes. 
Precise understanding of the consequences of ALS-related mutations and faithful 
modeling of contributing genetic and environmental factors leading to disease will 
elucidate disease mechanisms in ALS and related disorders, and it is our hope that 





Chapter 5: Materials and Methods 
 
Generation of mice and mouse genetics 
 All procedures were performed in accordance with the National Institutes of 
Health Guidelines on the Care and Use of Animals and approved by the Institutional 
Animal Care and Use Committee at Columbia University. 
 To generate knock-in mice, we cloned the mouse TARDBP gene from BAC clone 
RP23-291O2 into the targeting vector using recombineering methods. M337V or G298S 
mutations and a neomycin resistance cassette were inserted using overlap extension 
PCR and restriction cloning. The targeting construct was then electroporated into 
C57BL/6N embryonic stem cells and individual clones were picked and screened. 
Approximately 35% of clones had successfully undergone homologous recombination, 
as screened by Southern analysis and sequencing. Positive clones were injected into 
mouse blastocysts to generate chimeras, and germline transmitters were identified by 
genotyping and sequencing F1 pups. Mice were back-crossed to C57BL/6J to establish 
and maintain the lines. 
 Pgk1-FLPo (Stock #011065), Protamine-Cre (Stock #003328), and ChAT-IRES-
Cre (Stock #006410) mice were purchased from the Jackson Laboratory. Protamine-
Cre and ChAT-IRES-Cre were back-crossed to C57BL/6J for 6 generations. HnRNP U 
floxed mice were a generous gift from Dr. Tom Maniatis (Ye et al. 2015), and hnRNP U 
knockout allele was generated by crossing hnRNP U floxed mice to Protamine-Cre, 
selecting males with both alleles, and crossing back to C57BL/6J. τONhFUS mice were 
generated as described previously (Sharma et al. 2016). 
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 Genotyping primers are noted in Table 5.1. 
Tissue preparation for immunohistochemical analysis 
 Mice were anesthetized with intraperitoneal injections of ketamine (100 mg/kg, 
Ketaset, Pfizer) and xylazine (10 mg/kg Anased, Lloyd Laboratories). They were then 
transcardially perfused with 4% paraformaldehyde in 0.1M phosphate buffer, pH 7.4 
(PFA). Muscles were dissected immediately after perfusion and washed in 1x 
phosphate buffered saline, pH 7.4 (PBS). Muscles were prepared for cryosectioning by 
equilibrating in a sucrose gradient (10%-20%-30% sucrose in 0.1M PB) followed by 
embedding in O.C.T. compound (Sakura, Torrance, CA) and freezing at -20°C. Muscle 
was sectioned on cryostat at thickness of 40 µm and stored at -20°C. Spinal columns 
were fixed in PFA overnight and washed in 1x PBS.  Spinal cord segments were 
embedded in 4% agarose and transverse sections were cut at a thickness of 75 µm 
using a vibratome. 
Immunocytochemistry of spinal cord sections 
 Free floating spinal cord sections were blocked in 5% normal donkey serum in 
tris buffered saline, pH 7.4, with 0.5% Triton X-100 (TBS-T) for 1 hour at room 
temperature. Sections were incubated with primary antibodies overnight at room 
temperature (goat anti-ChAT, 1:250, Millipore; rabbit anti-TDP-43, 1:1000, Proteintech; 
rabbit anti-hnRNP U, 1:1000, abcam; rabbit anti-nup50, 1:1000, Proteintech). Sections 
were washed 6 X 20 minutes with TBS-T and incubated in secondary antibodies for 3 
hours at room temperature (donkey anti-goat Alexa 647, donkey anti-rabbit Alexa 555, 
donkey anti-rabbit Alexa 488 all at 1:1000). Sections were washed 6 X 20 minutes and 
mounted on microscope slides in Fluoromount G (Southern Biotech, Birmingham, AL, 
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USA). Slides were imaged using SP5 and SP8 Leica confocal microscopes (Leica 
Microsystems, Wetzlar, Germany). 
MN counts 
 Lumbar level 4 and lumbar level 5 (L4 and L5) segments were identified, 
sectioned, and stained as described previously. For adults (> 2 months old) a confocal 
z-series was imaged for every fourth section at 20X magnification with a step size of 2.0 
μm. For pups, L5 section was counted. MNs (labelled with anti-ChAT) in the lateral 
motor column were outlined in the confocal plane of the nucleolus and counted using 
ImageJ. 
Muscle innervation analysis 
 Tibialis anterior, diaphragm, and tongue muscles were dissected, equilibrated in 
sucrose gradient (10%, 20%, 30%), and embedded in O.C.T compound. Cryosections 
were cut serially on a freezing microtome (Leica CM 3050S) at thickness of 40 µm and 
stained with antibodies against synaptophysin to identify the presynaptic terminal (rabbi 
anti-synaptophysin, 1:500, Zymed) and tetramethylrhodamine-conjugated α-
Bungarotoxin (1:1000, Invitrogen) to identify the post-synaptic acetylcholine receptors at 
the NMJ. A confocal z-series was imaged at 10X magnification with a step size of 10 
µm. Synapses were identified with α-Bungarotoxin and subsequently innervation was 
determined by synaptophysin colocalization (presence or absence). At least 1000 NMJs 
were counted per animal. 
Measurement of GFAP and Iba1 positive cells 
 Lumbar motor neuron sections were stained with ChAT, GFAP (mouse anti-
GFAP, 1:400, sigma), and Iba1 (rabbit anti-Iba1, 1:5000, Wako). A confocal z-series 
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was imaged as previously described. A motor neuron was identified in ImageJ and a 
circle of radius 100 µm was drawn around the motor neuron. GFAP and Iba1 positive 
cells were counted within the circle in the z-planes containing the motor neuron nucleus. 
At least 10 cells were averaged per animal. 
Protein extraction and quantification 
 Brain and spinal cord samples were homogenized in Tris-Glycine SDS sample 
buffer using first a 23G and then a 27G syringe. Samples were sonicated 3X 5 seconds 
at 4°C and centrifuged for 20 minutes at 20,000 RCF at 4°C. Supernatant was kept as 
lysate. Lysate was denatured for 10 minutes at 95°C and quantified using the RC DC 
Protein Assay kit (Bio-Rad). Lysate (10-20 µg) was run on a 10% SDS-PAGE gel and 
transferred onto nitrocellulose membrane using a TE77x semidry transfer unit (Hoefer). 
Immunoblots were probed with antibodies (Table 5.2) in 4% milk in tris buffered saline, 
pH 7.4, with 0.1% Tween. Antibody was detected by incubation with horseradish 
peroxidase-conjugated secondary antibodies (Jackson Immunoresearch) followed by 
chemiluminescence using SuperSignal West Pico chemiluminescent substrate (Thermo 
Scientific). Signal was detected with autoradiography using LucentBlue X-Ray film, and 
relative protein levels were quantified using ImageJ. 
RNA extraction and quantification 
 Work space in laminar flow hood and all materials were cleaned with RNaseZap. 
Brain and spinal cord samples were homogenized in Trizol using first a 23G and then a 
27G syringe. RNA was isolated using Direct-zol RNA MiniPrep kit (Zymo Research) and 
quantified using a nanodrop. CDNA was synthesized using RevertAid First Strand 
cDNA Synthesis Kit (Fermentas). For RT-qPCR, each sample was measured in 
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triplicate using a Mastercycler ep Realplex4 (Eppendorf) PCR system and Power SYBR 
Green PCR Master Mix (ABI). TDP-43 levels were normalized to GAPDH. Primers are 
indicated in Table 5.1. 
Solubility fractionation 
 Protocol was followed as described (Jo et al. 2014). Brain samples were 
homogenized in soluble buffer and centrifuged at 50,000 RCF for 20 minutes at 4°C. 
Supernatant was removed as soluble fraction and pellet was resuspended in RAB 
buffer. Sample was vortexed and incubated at 4°C overnight with rotation. Sample was 
then centrifuged at 200,000 RCF for 30 minutes at 12°C and the supernatant was 
removed as the sarkosyl soluble fraction. Pellet was resuspended in RAB buffer, 
homogenized with 27G needle, and kept as insoluble fraction. Equivalent portions were 
aliquoted, added to 2X sample buffer, denatured at 95°C, and run on SDS-PAGE gel as 
previously described. 
Co-immunoprecipitation 
 Spinal cords were lysed on ice for co-immunoprecipitation (COIP) with 800 µL of 
lysis buffer containing 50 mM Tris-HCl pH 7.4, 1% Nonidet P-40, 0.25% sodium 
deoxycholate, 150 mM NaCl, 1 mM EDTA and supplemented with Pierce protease and 
phosphatase inhibitor tablets (Gal et al. 2007). Samples were homogenized with 16G, 
23G, and 27G needles and rotated for 30 minutes at 4°C. Samples were subsequently 
spun down at 20,000 RCF at 4°C, and supernatant was removed as lysate. Protein 
concentration was quantified using Bradford protein assay (Bio-Rad), and protein was 
then added to beads in a total volume of 500 µL. For RNAse treatment, lysate was 
pretreated for 45 minutes on ice with 10 µg RNAse A before mixing with beads. 
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 While samples were lysing, 40 µL Protein G Dynabeads per COIP were washed 
with 0.02% Tween in PBS. They were subsequently resuspended in 500 µL 0.02% 
Tween in PBS with COIP antibody (mouse anti-myc, 4 µL per COIP, Millipore or rabbit 
anti-hnRNP U, 5 µL per COIP, Bethyl) and rotated at room temperature for 45 minutes 
to crosslink antibody to the beads. Beads were then washed 3X with lysis buffer and 
stored on ice until adding lysate. COIPs were then rotated overnight at 4°C. In the 
morning, COIPs were washed 4X with cold lysis buffer. Beads were then resuspended 
in 1X LDS with reducing agent, heated at 70°C for 15 minutes, and samples were then 
run on a gel as described above. For western, antibodies were used as described in 
Table 5.2. For visualizing proteins, Silver Stain Plus Kit (Bio-Rad) and colloidal blue 
staining kit (Invitrogen) was used. For mass spectrometry, proteins were stained with 
colloidal blue, excised, digested, and analyzed by the Columbia University Proteomics 
Core Facility. Proteins that interact with hFUS were identified by spectral counts. 
Mouse weights and survival 
 For weights, mice were weighed between 9AM-11AM. To determine if a mouse 
was “end stage”, they were placed on their back or side, upon which their reflex is to 
right themselves on 4 paws. When they were too weak to right themselves in 15 
seconds or less, they were considered “endstage” and euthanized. 
Patient Samples 
 Patient samples were obtained from the Columbia Brain Bank with written 
consent from patients prior to autopsy. 
Immunocytochemistry of patient samples 
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 Spinal cord samples were obtained from the Columbia Brain Bank, embedded in 
pre-chilled O.C.T., and sections were cut on a freezing microtome at a thickness of 20 
µm. Sections were either stored at -80°C or used for staining. For staining, sections 
were washed with PBS for 5 minutes and then fixed with 4% paraformaldehyde at room 
temperature for 15 minutes. Sections were then washed 3 X 5 minutes with PBS, 
blocked with 5% normal donkey serum diluted in TBS-T and incubated with primary 
antibodies in TBS-T at 4°C overnight. Primary antibodies used were rabbit anti-hnRNP 
U, 1:1000, abcam; guinea pig anti-FUS, 1:16,000, generous gift from Susan Morton; 
and mouse anti-NeuN, 1:1000, Millipore. Sections were washed 3 X 10 minutes with 
TBS-T at room temperature and incubated with secondary antibodies for one hour at 
room temperature (donkey anti-rabbit Alexa 488 at 1:1000, donkey anti-mouse Alexa 
647 at 1:1000, donkey anti-guinea pig Cy3 at 1:500). Sections were then washed 3 X 10 
minutes with TBS-T and mounted with Fluoromount G. 
Yeast strains 
 Yeast protocols were followed as described (Johnson et al. 2009) and conducted 
with help from Dr. Rio Higuchi-Sanabria in Dr. Liza Pon’s lab. Yeast were grown in rich 
medium (YPD) or in synthetic media without uracil with 2% glucose, raffinose, or 
galactose. Mouse and human full length TDP-43 were cloned into the pRS416GAL 
vector and transformed into BY4741. 
Yeast spotting assay 
 Yeast were grown at 30°C in raffinose media overnight until reaching the log 
phase. Cultures were then serially diluted 10-fold and spotted onto plates containing 
either glucose or galactose and grown at 30°C for 3 days. 
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Yeast growth rate assay 
 Growth rate was measured as described previously (Vevea et al. 2015) with help 
from Dr. Liza Pon’s lab. Growth curves were measured with an automated plate reader 
(Tecan; Infinite M200, Research Triangle Park, NC). Strains were grown to mid-log 
phase in raffinose media and diluted to OD600 of 0.07. 10 µL of diluted yeast were added 
to wells in a 96-well plate containing 200 µL of either glucose or galactose media, and 
samples were plated in quadruplicate. Yeast were grown at 30°C and OD600 
measurements were made every 20 minutes for 3 days. The maximum growth rate was 
estimated using the greatest change in OD600 over a 4 hour interval. 
Statistical analysis 
 For all statistical analysis Graph Pad Prism 6 software was used. Statistical 
analysis of mean differences between groups was performed using one- or two-way 





Primer Target Sequence Use 
5' TDP KIN probe FWD Mouse genomic CAGCCAGTCAGATATATTTTAATACC Southern probe 
5' TDP KIN probe REV Mouse genomic ATAAAACCAAACCCATGGACATAC Southern probe 
3' TDP KIN probe FWD Mouse genomic CTTGAAAAATGTTGATTCTTGAGC Southern probe 
3' TDP KIN probe REV Mouse genomic AGCAAGCTAAAGTTATTCTTGCAG Southern probe 
TDP seq FWD TARDBP TGCTGTGTTGATATCTGGGTTGATC Sequencing 
TDP seq REV TARDBP TCTACCTAACCTAATAACCAACCTAC Sequencing 
TDP KIN Neo FWD Neo cassette GTATAGGAACTTCGTCGACGTC Genotyping 
TDP KIN FWD TARDBP GTTGGTCATTTGTCCCAGGGCTG Genotyping 
TDP KIN REV TARDBP GGAAAAACAGGCAATTTACTTAAAC Genotyping 
TDP FWD TARDBP GATAAGGTTGCCCAGTCTCTTTGTG qPCR 
TDP REV TARDBP TTCCACTTCTTTCTAACTGTCTATTGC qPCR 
GAPDH FWD GAPDH AATGTGTCCGTCGTGGATCTGA qPCR 
GAPDH REV GAPDH GATGCCTGCTTCACCACCTTCT qPCR 
hnRNP U FWD hnRNP U TCAGCAGCGAATGGTATCAA Genotyping 
hnRNP U FLOX REV hnRNP U GAAAGCAGCCATGTTTTACACTT Genotyping 
hnRNP U KO REV hnRNP U TTCCCAATTATGCCAATTCC Genotyping 
 




Protein Host Source 
TDP-43 rabbit Proteintech 10782-2-AP 
GAPDH mouse Millipore MAB374 
hnRNP U rabbit Abcam ab2066 
myc mouse Invitrogen 46-0603 
SFPQ rabbit Abcam ab38148 
Caprin 1 rabbit Proteintech 15112-1-AP 
hnRNP R mouse Livio Pellizzoni 
hnRNP Q mouse Livio Pellizzoni 
hnRNP K mouse Livio Pellizzoni 
Ddx1 rabbit Livio Pellizzoni 
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